{ "instance": { "fs42021a1_cmlifesci3.htm": { "axisCustom": 0, "axisStandard": 23, "contextCount": 303, "dts": { "calculationLink": { "local": [ "cmlt-20210630_cal.xml" ] }, "definitionLink": { "local": [ "cmlt-20210630_def.xml" ] }, "inline": { "local": [ "fs42021a1_cmlifesci3.htm" ] }, "labelLink": { "local": [ "cmlt-20210630_lab.xml" ] }, "presentationLink": { "local": [ "cmlt-20210630_pre.xml" ] }, "schema": { "local": [ "cmlt-20210630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 844, "entityCount": 1, "hidden": { "http://cmlifesciencesspac.com/20210630": 51, "http://fasb.org/us-gaap/2021-01-31": 181, "http://xbrl.sec.gov/dei/2021": 3, "total": 235 }, "keyCustom": 195, "keyStandard": 407, "memberCustom": 32, "memberStandard": 30, "nsprefix": "cmlt", "nsuri": "http://cmlifesciencesspac.com/20210630", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://cmlifesciencesspac.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c17", "decimals": null, "first": true, "lang": "en-US", "name": "cmlt:InitialPublicOfferingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Initial Public Offering", "role": "http://cmlifesciencesspac.com/role/InitialPublicOffering", "shortName": "Initial Public Offering", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c17", "decimals": null, "first": true, "lang": "en-US", "name": "cmlt:InitialPublicOfferingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c155", "decimals": null, "first": true, "lang": "en-US", "name": "cmlt:PrivatePlacementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Private Placement", "role": "http://cmlifesciencesspac.com/role/PrivatePlacement", "shortName": "Private Placement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c155", "decimals": null, "first": true, "lang": "en-US", "name": "cmlt:PrivatePlacementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c22", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Related Party Transactions", "role": "http://cmlifesciencesspac.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c22", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c155", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Commitments and Contingencies", "role": "http://cmlifesciencesspac.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c155", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c22", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Stockholders' Equity", "role": "http://cmlifesciencesspac.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c22", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c17", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Derivative Warrant Liabilities", "role": "http://cmlifesciencesspac.com/role/DerivativeWarrantLiabilities", "shortName": "Derivative Warrant Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c17", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c17", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Fair Value Measurements", "role": "http://cmlifesciencesspac.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c17", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c155", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Subsequent Events", "role": "http://cmlifesciencesspac.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c155", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c155", "decimals": null, "first": true, "lang": "en-US", "name": "cmlt:ProposedPublicOfferingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Proposed Public Offering", "role": "http://cmlifesciencesspac.com/role/ProposedPublicOffering", "shortName": "Proposed Public Offering", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c155", "decimals": null, "first": true, "lang": "en-US", "name": "cmlt:ProposedPublicOfferingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Nature of Business", "role": "http://cmlifesciencesspac.com/role/NatureofBusiness", "shortName": "Nature of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Balance Sheet", "role": "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet", "shortName": "Balance Sheet", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c1", "decimals": "0", "lang": null, "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Cash, Cash Equivalents and Restricted Cash", "role": "http://cmlifesciencesspac.com/role/CashCashEquivalentsandRestrictedCash", "shortName": "Cash, Cash Equivalents and Restricted Cash", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Property and Equipment, Net", "role": "http://cmlifesciencesspac.com/role/PropertyandEquipmentNet", "shortName": "Property and Equipment, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c273", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Accrued Expenses", "role": "http://cmlifesciencesspac.com/role/AccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c273", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": null, "first": true, "lang": "en-US", "name": "cmlt:ConvertiblePreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Convertible Preferred Stock", "role": "http://cmlifesciencesspac.com/role/ConvertiblePreferredStock", "shortName": "Convertible Preferred Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": null, "first": true, "lang": "en-US", "name": "cmlt:ConvertiblePreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": null, "first": true, "lang": "en-US", "name": "cmlt:CommonStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Common Stock", "role": "http://cmlifesciencesspac.com/role/CommonStock", "shortName": "Common Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": null, "first": true, "lang": "en-US", "name": "cmlt:CommonStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Stock-Based Compensation", "role": "http://cmlifesciencesspac.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": null, "first": true, "lang": "en-US", "name": "cmlt:LicenseAgreementsAndDiscoveryCollaborationsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - License Agreements and Discovery Collaborations", "role": "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborations", "shortName": "License Agreements and Discovery Collaborations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": null, "first": true, "lang": "en-US", "name": "cmlt:LicenseAgreementsAndDiscoveryCollaborationsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c273", "decimals": null, "first": true, "lang": "en-US", "name": "cmlt:EmployeeBenefitsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Employee Benefits", "role": "http://cmlifesciencesspac.com/role/EmployeeBenefits", "shortName": "Employee Benefits", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c273", "decimals": null, "first": true, "lang": "en-US", "name": "cmlt:EmployeeBenefitsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Net Loss Per Share", "role": "http://cmlifesciencesspac.com/role/NetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c25", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Convertible Promissory Notes", "role": "http://cmlifesciencesspac.com/role/ConvertiblePromissoryNotes", "shortName": "Convertible Promissory Notes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c25", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c1", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Balance Sheet (Parentheticals)", "role": "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Balance Sheet (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c2", "decimals": "4", "lang": null, "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c25", "decimals": null, "first": true, "lang": "en-US", "name": "cmlt:LicenseAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - License Agreements", "role": "http://cmlifesciencesspac.com/role/LicenseAgreements", "shortName": "License Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c25", "decimals": null, "first": true, "lang": "en-US", "name": "cmlt:LicenseAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c25", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Income Taxes", "role": "http://cmlifesciencesspac.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c25", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c154", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Accounting Policies, by Policy (Policies)", "role": "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c154", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c17", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "role": "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c17", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c17", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Fair Value Measurements (Tables)", "role": "http://cmlifesciencesspac.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c17", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables)", "role": "http://cmlifesciencesspac.com/role/CashCashEquivalentsandRestrictedCashTables", "shortName": "Cash, Cash Equivalents and Restricted Cash (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Property and Equipment, Net (Tables)", "role": "http://cmlifesciencesspac.com/role/PropertyandEquipmentNetTables", "shortName": "Property and Equipment, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c273", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Accrued Expenses (Tables)", "role": "http://cmlifesciencesspac.com/role/AccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c273", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfConversionsOfStockTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Convertible Preferred Stock (Tables)", "role": "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockTables", "shortName": "Convertible Preferred Stock (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://cmlifesciencesspac.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c22", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Condensed Consolidated Statements of Operations", "role": "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c22", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Commitment and Contingencies (Tables)", "role": "http://cmlifesciencesspac.com/role/CommitmentandContingenciesTables", "shortName": "Commitment and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": null, "first": true, "lang": "en-US", "name": "cmlt:ScheduleOfComputationOfBasicAndDilutedNetLossPerShareTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Net Loss Per Share (Tables)", "role": "http://cmlifesciencesspac.com/role/NetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": null, "first": true, "lang": "en-US", "name": "cmlt:ScheduleOfComputationOfBasicAndDilutedNetLossPerShareTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfConversionsOfStockTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Convertible Preferred Stock (Tables)", "role": "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockTables0", "shortName": "Convertible Preferred Stock (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R43": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c25", "decimals": null, "first": true, "lang": "en-US", "name": "cmlt:ScheduleOfOperationsAndComprehensiveLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Commitment and Contingencies (Tables)", "role": "http://cmlifesciencesspac.com/role/CommitmentandContingenciesTables0", "shortName": "Commitment and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c25", "decimals": null, "first": true, "lang": "en-US", "name": "cmlt:ScheduleOfOperationsAndComprehensiveLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c25", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Income Taxes (Tables)", "role": "http://cmlifesciencesspac.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c25", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c105", "decimals": "-5", "first": true, "lang": null, "name": "cmlt:GrossProceeds", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Description of Organization and Business Operations (Details)", "role": "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "shortName": "Description of Organization and Business Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c17", "decimals": "2", "lang": null, "name": "cmlt:ExercisablePriceOfWarrants", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c17", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FederalDepositInsuranceCorporationPremiumExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details)", "role": "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c17", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FederalDepositInsuranceCorporationPremiumExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c18", "decimals": "0", "first": true, "lang": null, "name": "cmlt:IncomeFromInvestmentsHeldInTrustAccount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of basic and diluted net income (loss) per common share", "role": "http://cmlifesciencesspac.com/role/ScheduleofbasicanddilutednetincomelosspercommonshareTable", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of basic and diluted net income (loss) per common share", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c18", "decimals": "0", "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c4", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SaleOfStockPricePerShare", "reportCount": 1, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Initial Public Offering (Details)", "role": "http://cmlifesciencesspac.com/role/InitialPublicOfferingDetails", "shortName": "Initial Public Offering (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c105", "decimals": "-5", "lang": null, "name": "us-gaap:DeferredCostsCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Private Placement (Details)", "role": "http://cmlifesciencesspac.com/role/PrivatePlacementDetails", "shortName": "Private Placement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c94", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Condensed Consolidated Statement of Changes in Stockholders\u2019 Equity (Deficit)", "role": "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3", "shortName": "Condensed Consolidated Statement of Changes in Stockholders\u2019 Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c94", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c4", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SaleOfStockPricePerShare", "reportCount": 1, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Related Party Transactions (Details)", "role": "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c129", "decimals": null, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c241", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseExpirationDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Commitments and Contingencies (Details)", "role": "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c241", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseExpirationDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Stockholders' Equity (Details)", "role": "http://cmlifesciencesspac.com/role/StockholdersEquityDetails", "shortName": "Stockholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c22", "decimals": null, "lang": "en-US", "name": "us-gaap:CommonStockVotingRights", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c17", "decimals": "0", "first": true, "lang": null, "name": "cmlt:PublicWarrants", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Derivative Warrant Liabilities (Details)", "role": "http://cmlifesciencesspac.com/role/DerivativeWarrantLiabilitiesDetails", "shortName": "Derivative Warrant Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c17", "decimals": "0", "first": true, "lang": null, "name": "cmlt:PublicWarrants", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c135", "decimals": "0", "first": true, "lang": null, "name": "cmlt:RecognizedLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Fair Value Measurements (Details)", "role": "http://cmlifesciencesspac.com/role/FairValueMeasurementsDetails", "shortName": "Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c135", "decimals": "0", "first": true, "lang": null, "name": "cmlt:RecognizedLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c136", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetsHeldInTrustCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "054 - Disclosure - Fair Value Measurements (Details) - Schedule of assets that are measured at fair value on a recurring basis", "role": "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable", "shortName": "Fair Value Measurements (Details) - Schedule of assets that are measured at fair value on a recurring basis", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c136", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetsHeldInTrustCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c138", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "055 - Disclosure - Fair Value Measurements (Details) - Schedule of provides quantitative information regarding Level 3 fair value measurements", "role": "http://cmlifesciencesspac.com/role/ScheduleofprovidesquantitativeinformationregardingLevel3fairvaluemeasurementsTable", "shortName": "Fair Value Measurements (Details) - Schedule of provides quantitative information regarding Level 3 fair value measurements", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c138", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c16", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfWarrants", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "056 - Disclosure - Fair Value Measurements (Details) - Schedule of derivative warrant liabilities", "role": "http://cmlifesciencesspac.com/role/ScheduleofderivativewarrantliabilitiesTable", "shortName": "Fair Value Measurements (Details) - Schedule of derivative warrant liabilities", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c16", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfWarrants", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c184", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TemporaryEquitySharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "057 - Disclosure - Subsequent Events (Details)", "role": "http://cmlifesciencesspac.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c184", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TemporaryEquitySharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c4", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SaleOfStockPricePerShare", "reportCount": 1, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "058 - Disclosure - Proposed Public Offering (Details)", "role": "http://cmlifesciencesspac.com/role/ProposedPublicOfferingDetails", "shortName": "Proposed Public Offering (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c159", "decimals": null, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c60", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Condensed Consolidated Statement of Changes in Stockholders\u2019 Equity (Deficit) (Parentheticals)", "role": "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3_Parentheticals", "shortName": "Condensed Consolidated Statement of Changes in Stockholders\u2019 Equity (Deficit) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c60", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": "-5", "first": true, "lang": null, "name": "cmlt:NetLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "059 - Disclosure - Nature of Business (Details)", "role": "http://cmlifesciencesspac.com/role/NatureofBusinessDetails", "shortName": "Nature of Business (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": "-5", "first": true, "lang": null, "name": "cmlt:NetLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c7", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Details) - Schedule of condensed consolidated statements of cash flows", "role": "http://cmlifesciencesspac.com/role/ScheduleofcondensedconsolidatedstatementsofcashflowsTable", "shortName": "Cash, Cash Equivalents and Restricted Cash (Details) - Schedule of condensed consolidated statements of cash flows", "subGroupType": "details", "uniqueAnchor": null }, "R62": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c7", "decimals": "-3", "first": true, "lang": null, "name": "cmlt:AmortizedCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061 - Disclosure - Fair Value Measurements and Fair Value of Instruments (Details) - Schedule of assets that are measured at fair value on a recurring basis", "role": "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable0", "shortName": "Fair Value Measurements and Fair Value of Instruments (Details) - Schedule of assets that are measured at fair value on a recurring basis", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c7", "decimals": "-3", "first": true, "lang": null, "name": "cmlt:AmortizedCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "062 - Disclosure - Property and Equipment, Net (Details)", "role": "http://cmlifesciencesspac.com/role/PropertyandEquipmentNetDetails", "shortName": "Property and Equipment, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c7", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "063 - Disclosure - Property and Equipment, Net (Details) - Schedule of property and equipment, net", "role": "http://cmlifesciencesspac.com/role/ScheduleofpropertyandequipmentnetTable", "shortName": "Property and Equipment, Net (Details) - Schedule of property and equipment, net", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c201", "decimals": null, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": "-3", "first": true, "lang": null, "name": "cmlt:ExternalResearchAndDevelopment", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "064 - Disclosure - Accrued Expenses (Details) - Schedule of accrued expenses", "role": "http://cmlifesciencesspac.com/role/ScheduleofaccruedexpensesTable", "shortName": "Accrued Expenses (Details) - Schedule of accrued expenses", "subGroupType": "details", "uniqueAnchor": null }, "R66": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c7", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "065 - Disclosure - Convertible Preferred Stock (Details)", "role": "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails", "shortName": "Convertible Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c226", "decimals": "INF", "lang": null, "name": "cmlt:AdditionalShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfConversionsOfStockTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c7", "decimals": "INF", "first": true, "lang": null, "name": "cmlt:ShareAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "066 - Disclosure - Convertible Preferred Stock (Details) - Schedule of outstanding Convertible Preferred Stock", "role": "http://cmlifesciencesspac.com/role/ScheduleofoutstandingConvertiblePreferredStockTable", "shortName": "Convertible Preferred Stock (Details) - Schedule of outstanding Convertible Preferred Stock", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfConversionsOfStockTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c7", "decimals": "INF", "first": true, "lang": null, "name": "cmlt:ShareAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c7", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "067 - Disclosure - Common Stock (Details)", "role": "http://cmlifesciencesspac.com/role/CommonStockDetails", "shortName": "Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": "INF", "lang": null, "name": "cmlt:CommonStockIssuedSharesSold", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c7", "decimals": "INF", "first": true, "lang": null, "name": "cmlt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRemaingAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "068 - Disclosure - Stock-Based Compensation (Details)", "role": "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails", "shortName": "Stock-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c7", "decimals": "INF", "first": true, "lang": null, "name": "cmlt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRemaingAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c22", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Condensed Consolidated Statement of Cash Flows", "role": "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow", "shortName": "Condensed Consolidated Statement of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c17", "decimals": "0", "lang": null, "name": "us-gaap:OtherNoncashExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "069 - Disclosure - Stock-Based Compensation (Details) - Schedule of stock-based compensation expense", "role": "http://cmlifesciencesspac.com/role/ScheduleofstockbasedcompensationexpenseTable", "shortName": "Stock-Based Compensation (Details) - Schedule of stock-based compensation expense", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c233", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c7", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "070 - Disclosure - Stock-Based Compensation (Details) - Schedule of stock option activity for employee and nonemployee awards", "role": "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable", "shortName": "Stock-Based Compensation (Details) - Schedule of stock option activity for employee and nonemployee awards", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c7", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "071 - Disclosure - Stock-Based Compensation (Details) - Schedule of weighted-average assumption", "role": "http://cmlifesciencesspac.com/role/ScheduleofweightedaverageassumptionTable", "shortName": "Stock-Based Compensation (Details) - Schedule of weighted-average assumption", "subGroupType": "details", "uniqueAnchor": null }, "R73": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c232", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "072 - Disclosure - Stock-Based Compensation (Details) - Schedule of restricted stock activity", "role": "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable", "shortName": "Stock-Based Compensation (Details) - Schedule of restricted stock activity", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c232", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": "-5", "first": true, "lang": null, "name": "cmlt:NoncreditablePayment", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "073 - Disclosure - License Agreements and Discovery Collaborations (Details)", "role": "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborationsDetails", "shortName": "License Agreements and Discovery Collaborations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": "-5", "lang": null, "name": "cmlt:TargetFee", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c249", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "074 - Disclosure - Commitment and Contingencies (Details) - Schedule of lease costs in the Company\u2019s condensed consolidated statements of operations and comprehensive loss", "role": "http://cmlifesciencesspac.com/role/ScheduleofleasecostsintheCompanyscondensedconsolidatedstatementsofoperationsandcomprehensivelossTable", "shortName": "Commitment and Contingencies (Details) - Schedule of lease costs in the Company\u2019s condensed consolidated statements of operations and comprehensive loss", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c249", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanCostRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "075 - Disclosure - Employee Benefits (Details)", "role": "http://cmlifesciencesspac.com/role/EmployeeBenefitsDetails", "shortName": "Employee Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanCostRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "cmlt:ScheduleOfComputationOfBasicAndDilutedNetLossPerShareTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "076 - Disclosure - Net Loss Per Share (Details) - Schedule of computation of basic and diluted net loss per share", "role": "http://cmlifesciencesspac.com/role/ScheduleofcomputationofbasicanddilutednetlosspershareTable", "shortName": "Net Loss Per Share (Details) - Schedule of computation of basic and diluted net loss per share", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "cmlt:ScheduleOfComputationOfBasicAndDilutedNetLossPerShareTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "cmlt:ScheduleOfConvertiblePreferredStockOptionsToPurchaseCommonStockAndUnvestedRestrictedStockTableTextblock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c7", "decimals": "INF", "first": true, "lang": null, "name": "cmlt:ConvertiblePreferredShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "077 - Disclosure - Net Loss Per Share (Details) - Schedule of convertible preferred stock, options to purchase common stock and unvested restricted stock", "role": "http://cmlifesciencesspac.com/role/ScheduleofconvertiblepreferredstockoptionstopurchasecommonstockandunvestedrestrictedstockTable", "shortName": "Net Loss Per Share (Details) - Schedule of convertible preferred stock, options to purchase common stock and unvested restricted stock", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "cmlt:ScheduleOfConvertiblePreferredStockOptionsToPurchaseCommonStockAndUnvestedRestrictedStockTableTextblock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c7", "decimals": "INF", "first": true, "lang": null, "name": "cmlt:ConvertiblePreferredShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c7", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "078 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of consolidated statement of cash flows", "role": "http://cmlifesciencesspac.com/role/ScheduleofconsolidatedstatementofcashflowsTable", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of consolidated statement of cash flows", "subGroupType": "details", "uniqueAnchor": null }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c22", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Description of Organization and Business Operations", "role": "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperations", "shortName": "Description of Organization and Business Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c22", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c8", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "079 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of fair value recurring basis and level of inputs used in such measurements", "role": "http://cmlifesciencesspac.com/role/ScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsTable", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of fair value recurring basis and level of inputs used in such measurements", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c8", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c8", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080 - Disclosure - Property and Equipment, Net (Details) - Schedule of property plant and equipment", "role": "http://cmlifesciencesspac.com/role/ScheduleofpropertyplantandequipmentTable", "shortName": "Property and Equipment, Net (Details) - Schedule of property plant and equipment", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c260", "decimals": null, "lang": "en-US", "name": "cmlt:EstimatedUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c271", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "081 - Disclosure - Convertible Promissory Notes (Details)", "role": "http://cmlifesciencesspac.com/role/ConvertiblePromissoryNotesDetails", "shortName": "Convertible Promissory Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c271", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": "-3", "first": true, "lang": null, "name": "cmlt:ExternalResearchAndDevelopment", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "082 - Disclosure - Accrued Expenses (Details) - Schedule of accrued expenses", "role": "http://cmlifesciencesspac.com/role/ScheduleofaccruedexpensesTable0", "shortName": "Accrued Expenses (Details) - Schedule of accrued expenses", "subGroupType": "details", "uniqueAnchor": null }, "R84": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfConversionsOfStockTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c273", "decimals": "INF", "first": true, "lang": null, "name": "cmlt:SharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "083 - Disclosure - Convertible Preferred Stock (Details) - Schedule of table summarize the Company\u2019s outstanding Convertible Preferred Stock", "role": "http://cmlifesciencesspac.com/role/ScheduleoftablesummarizetheCompanysoutstandingConvertiblePreferredStockTable", "shortName": "Convertible Preferred Stock (Details) - Schedule of table summarize the Company\u2019s outstanding Convertible Preferred Stock", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfConversionsOfStockTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c273", "decimals": "INF", "first": true, "lang": null, "name": "cmlt:SharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c25", "decimals": "0", "first": true, "lang": null, "name": "cmlt:OtherResearchAndDevelopmentExpenses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "084 - Disclosure - Stock-Based Compensation (Details) - Schedule of stock-based compensation expense", "role": "http://cmlifesciencesspac.com/role/ScheduleofstockbasedcompensationexpenseTable0", "shortName": "Stock-Based Compensation (Details) - Schedule of stock-based compensation expense", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c25", "decimals": "0", "first": true, "lang": null, "name": "cmlt:OtherResearchAndDevelopmentExpenses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c288", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "085 - Disclosure - Stock-Based Compensation (Details) - Schedule of stock option activity for employee and nonemployee awards", "role": "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable0", "shortName": "Stock-Based Compensation (Details) - Schedule of stock option activity for employee and nonemployee awards", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c288", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "086 - Disclosure - Stock-Based Compensation (Details) - Schedule of weighted-average assumptions", "role": "http://cmlifesciencesspac.com/role/ScheduleofweightedaverageassumptionsTable", "shortName": "Stock-Based Compensation (Details) - Schedule of weighted-average assumptions", "subGroupType": "details", "uniqueAnchor": null }, "R88": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c8", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "087 - Disclosure - Stock-Based Compensation (Details) - Schedule of restricted stock activity", "role": "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable0", "shortName": "Stock-Based Compensation (Details) - Schedule of restricted stock activity", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c8", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c23", "decimals": "-5", "first": true, "lang": null, "name": "cmlt:NoncreditablePayment", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "088 - Disclosure - License Agreements (Details)", "role": "http://cmlifesciencesspac.com/role/LicenseAgreementsDetails", "shortName": "License Agreements (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c22", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "role": "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c22", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "cmlt:ScheduleOfOperationsAndComprehensiveLossTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c273", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "089 - Disclosure - Commitment and Contingencies (Details) - Schedule of operations and comprehensive loss", "role": "http://cmlifesciencesspac.com/role/ScheduleofoperationsandcomprehensivelossTable", "shortName": "Commitment and Contingencies (Details) - Schedule of operations and comprehensive loss", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "cmlt:ScheduleOfOperationsAndComprehensiveLossTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c273", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "cmlt:ScheduleOfFutureMinimumLeasePaymentForOperatingLeasesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c282", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090 - Disclosure - Commitment and Contingencies (Details) - Schedule of total lease payment", "role": "http://cmlifesciencesspac.com/role/ScheduleoftotalleasepaymentTable", "shortName": "Commitment and Contingencies (Details) - Schedule of total lease payment", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "cmlt:ScheduleOfFutureMinimumLeasePaymentForOperatingLeasesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c282", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c26", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091 - Disclosure - Income Taxes (Details)", "role": "http://cmlifesciencesspac.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c26", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c26", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "092 - Disclosure - Income Taxes (Details) - Schedule of no provision for income taxes", "role": "http://cmlifesciencesspac.com/role/ScheduleofnoprovisionforincometaxesTable", "shortName": "Income Taxes (Details) - Schedule of no provision for income taxes", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c26", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c8", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "093 - Disclosure - Income Taxes (Details) - Schedule of net deferred tax assets", "role": "http://cmlifesciencesspac.com/role/ScheduleofnetdeferredtaxassetsTable", "shortName": "Income Taxes (Details) - Schedule of net deferred tax assets", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c8", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c26", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "094 - Disclosure - Net Loss Per Share (Details) - Schedule of computation of basic and diluted net loss per share", "role": "http://cmlifesciencesspac.com/role/ScheduleofcomputationofbasicanddilutednetlosspershareTable0", "shortName": "Net Loss Per Share (Details) - Schedule of computation of basic and diluted net loss per share", "subGroupType": "details", "uniqueAnchor": null }, "R96": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "cmlt:ScheduleOfConvertiblePreferredStockOptionsToPurchaseCommonStockAndUnvestedRestrictedStockTableTextblock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c8", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "095 - Disclosure - Net Loss Per Share (Details) - Schedule of convertible preferred stock, options to purchase common stock and unvested restricted stock", "role": "http://cmlifesciencesspac.com/role/ScheduleofconvertiblepreferredstockoptionstopurchasecommonstockandunvestedrestrictedstockTable0", "shortName": "Net Loss Per Share (Details) - Schedule of convertible preferred stock, options to purchase common stock and unvested restricted stock", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "cmlt:ScheduleOfConvertiblePreferredStockOptionsToPurchaseCommonStockAndUnvestedRestrictedStockTableTextblock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "fs42021a1_cmlifesci3.htm", "contextRef": "c8", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } } }, "segmentCount": 72, "tag": { "cmlt_AccountingPoliciesbyPolicyPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies, by Policy (Policies) [Line Items]" } } }, "localname": "AccountingPoliciesbyPolicyPoliciesLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "stringItemType" }, "cmlt_AccountingPoliciesbyPolicyPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies, by Policy (Policies) [Table]" } } }, "localname": "AccountingPoliciesbyPolicyPoliciesTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "stringItemType" }, "cmlt_AccruedExpensesDetailsScheduleofaccruedexpensesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Expenses (Details) - Schedule of accrued expenses [Line Items]" } } }, "localname": "AccruedExpensesDetailsScheduleofaccruedexpensesLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofaccruedexpensesTable", "http://cmlifesciencesspac.com/role/ScheduleofaccruedexpensesTable0" ], "xbrltype": "stringItemType" }, "cmlt_AccruedExpensesDetailsScheduleofaccruedexpensesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Expenses (Details) - Schedule of accrued expenses [Table]" } } }, "localname": "AccruedExpensesDetailsScheduleofaccruedexpensesTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofaccruedexpensesTable", "http://cmlifesciencesspac.com/role/ScheduleofaccruedexpensesTable0" ], "xbrltype": "stringItemType" }, "cmlt_AccruedExpensesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Expenses [Line Items]" } } }, "localname": "AccruedExpensesLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/AccruedExpenses" ], "xbrltype": "stringItemType" }, "cmlt_AccruedExpensesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Expenses [Table]" } } }, "localname": "AccruedExpensesTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/AccruedExpenses" ], "xbrltype": "stringItemType" }, "cmlt_AccruedExpensesTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Expenses (Tables) [Line Items]" } } }, "localname": "AccruedExpensesTablesLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/AccruedExpensesTables" ], "xbrltype": "stringItemType" }, "cmlt_AccruedExpensesTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Expenses (Tables) [Table]" } } }, "localname": "AccruedExpensesTablesTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/AccruedExpensesTables" ], "xbrltype": "stringItemType" }, "cmlt_AccruedProfessionalServices": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "AccruedProfessionalServices", "terseLabel": "Accrued professional services" } } }, "localname": "AccruedProfessionalServices", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofaccruedexpensesTable", "http://cmlifesciencesspac.com/role/ScheduleofaccruedexpensesTable0" ], "xbrltype": "monetaryItemType" }, "cmlt_AdditionalBorrowedAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "AdditionalBorrowedAmount", "terseLabel": "Additional borrowed amount" } } }, "localname": "AdditionalBorrowedAmount", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_AdditionalShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional shares.", "label": "AdditionalShares", "terseLabel": "Additional shares" } } }, "localname": "AdditionalShares", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "sharesItemType" }, "cmlt_AggregateAmountOfCommonStockPurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate amount Of common Stock purchased.", "label": "AggregateAmountOfCommonStockPurchased", "terseLabel": "Aggregate shares purchased" } } }, "localname": "AggregateAmountOfCommonStockPurchased", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "cmlt_AggregateAmountOfCommonStockValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate amount of common stock value.", "label": "AggregateAmountOfCommonStockValue", "terseLabel": "Aggregate amount (in Dollars)" } } }, "localname": "AggregateAmountOfCommonStockValue", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_AggregateFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate fair value", "label": "AggregateFairValue", "terseLabel": "Aggregate Fair Value", "verboseLabel": "Aggregate fair value" } } }, "localname": "AggregateFairValue", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/FairValueMeasurementsDetails", "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable0" ], "xbrltype": "monetaryItemType" }, "cmlt_AggregateGrossProceeds": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AggregateGrossProceeds", "terseLabel": "Aggregate gross proceeds" } } }, "localname": "AggregateGrossProceeds", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "cmlt_AggregateIntrinsicValueOutstandingValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "AggregateIntrinsicValueOutstandingValue", "terseLabel": "Aggregate Intrinsic Value, Outstanding" } } }, "localname": "AggregateIntrinsicValueOutstandingValue", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable" ], "xbrltype": "monetaryItemType" }, "cmlt_AggregateIntrinsicValueVested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "AggregateIntrinsicValueVested", "terseLabel": "Aggregate Intrinsic Value, Vested" } } }, "localname": "AggregateIntrinsicValueVested", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable" ], "xbrltype": "monetaryItemType" }, "cmlt_AggregateIntrinsicValueVestedAndExpected": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "AggregateIntrinsicValueVestedAndExpected", "terseLabel": "Aggregate Intrinsic Value, Vested and expected" } } }, "localname": "AggregateIntrinsicValueVestedAndExpected", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable" ], "xbrltype": "monetaryItemType" }, "cmlt_AggregateIntrinsicValuesOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "AggregateIntrinsicValuesOutstanding", "terseLabel": "Aggregate Intrinsic Value Outstanding" } } }, "localname": "AggregateIntrinsicValuesOutstanding", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable" ], "xbrltype": "monetaryItemType" }, "cmlt_AggregateOfPurchasePrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate of purchase price.", "label": "AggregateOfPurchasePrice", "terseLabel": "Aggregate of purchase price" } } }, "localname": "AggregateOfPurchasePrice", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_AggregateOfPurchasesPrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate of purchases price.", "label": "AggregateOfPurchasesPrice", "terseLabel": "Aggregate of purchases price" } } }, "localname": "AggregateOfPurchasesPrice", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_AggregatePrivatePlacementWarrant": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "AggregatePrivatePlacementWarrant", "label": "AggregatePrivatePlacementWarrant", "terseLabel": "Aggregate private placement warrant" } } }, "localname": "AggregatePrivatePlacementWarrant", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_AggregatesOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregates of shares.", "label": "AggregatesOfShares", "terseLabel": "Aggregates of shares" } } }, "localname": "AggregatesOfShares", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "cmlt_AggregrateProceeds": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "AggregrateProceeds", "terseLabel": "Aggregate proceeds (in Dollars)" } } }, "localname": "AggregrateProceeds", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_AmortizedCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized Costs.", "label": "AmortizedCosts", "terseLabel": "Amortized Costs" } } }, "localname": "AmortizedCosts", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable0" ], "xbrltype": "monetaryItemType" }, "cmlt_AssetsInvestmentsInTrustAccountAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AssetsInvestmentsInTrustAccountAbstract", "terseLabel": "Assets: Investments in Trust Account" } } }, "localname": "AssetsInvestmentsInTrustAccountAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "stringItemType" }, "cmlt_BasicAndDilutedNetIncomePerShareinDollarsPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BasicAndDilutedNetIncomePerShareinDollarsPerShare", "terseLabel": "Basic and diluted net income per share (in Dollars per share)" } } }, "localname": "BasicAndDilutedNetIncomePerShareinDollarsPerShare", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofbasicanddilutednetincomelosspercommonshareTable" ], "xbrltype": "perShareItemType" }, "cmlt_BasicAndDilutedWeightedAverageSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BasicAndDilutedWeightedAverageSharesOutstanding", "terseLabel": "Basic and diluted weighted average shares outstanding (in Shares)" } } }, "localname": "BasicAndDilutedWeightedAverageSharesOutstanding", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofbasicanddilutednetincomelosspercommonshareTable" ], "xbrltype": "sharesItemType" }, "cmlt_BasisofPresentationandSummaryofSignificantAccountingPoliciesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Summary of Significant Accounting Policies (Details) [Line Items]" } } }, "localname": "BasisofPresentationandSummaryofSignificantAccountingPoliciesDetailsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "cmlt_BasisofPresentationandSummaryofSignificantAccountingPoliciesDetailsScheduleofbasicanddilutednetincomelosspercommonshareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of basic and diluted net income (loss) per common share [Line Items]" } } }, "localname": "BasisofPresentationandSummaryofSignificantAccountingPoliciesDetailsScheduleofbasicanddilutednetincomelosspercommonshareLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofbasicanddilutednetincomelosspercommonshareTable" ], "xbrltype": "stringItemType" }, "cmlt_BasisofPresentationandSummaryofSignificantAccountingPoliciesDetailsScheduleofbasicanddilutednetincomelosspercommonshareTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of basic and diluted net income (loss) per common share [Table]" } } }, "localname": "BasisofPresentationandSummaryofSignificantAccountingPoliciesDetailsScheduleofbasicanddilutednetincomelosspercommonshareTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofbasicanddilutednetincomelosspercommonshareTable" ], "xbrltype": "stringItemType" }, "cmlt_BasisofPresentationandSummaryofSignificantAccountingPoliciesDetailsScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of fair value recurring basis and level of inputs used in such measurements [Line Items]" } } }, "localname": "BasisofPresentationandSummaryofSignificantAccountingPoliciesDetailsScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsTable" ], "xbrltype": "stringItemType" }, "cmlt_BasisofPresentationandSummaryofSignificantAccountingPoliciesDetailsScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of fair value recurring basis and level of inputs used in such measurements [Table]" } } }, "localname": "BasisofPresentationandSummaryofSignificantAccountingPoliciesDetailsScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsTable" ], "xbrltype": "stringItemType" }, "cmlt_BasisofPresentationandSummaryofSignificantAccountingPoliciesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Summary of Significant Accounting Policies (Details) [Table]" } } }, "localname": "BasisofPresentationandSummaryofSignificantAccountingPoliciesDetailsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "cmlt_BasisofPresentationandSummaryofSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Summary of Significant Accounting Policies [Line Items]" } } }, "localname": "BasisofPresentationandSummaryofSignificantAccountingPoliciesLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" ], "xbrltype": "stringItemType" }, "cmlt_BasisofPresentationandSummaryofSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Summary of Significant Accounting Policies [Table]" } } }, "localname": "BasisofPresentationandSummaryofSignificantAccountingPoliciesTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" ], "xbrltype": "stringItemType" }, "cmlt_BasisofPresentationandSummaryofSignificantAccountingPoliciesTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Summary of Significant Accounting Policies (Tables) [Line Items]" } } }, "localname": "BasisofPresentationandSummaryofSignificantAccountingPoliciesTablesLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "stringItemType" }, "cmlt_BasisofPresentationandSummaryofSignificantAccountingPoliciesTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Summary of Significant Accounting Policies (Tables) [Table]" } } }, "localname": "BasisofPresentationandSummaryofSignificantAccountingPoliciesTablesTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "stringItemType" }, "cmlt_BusinessCombinationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BusinessCombinationMember", "terseLabel": "Business Combination [Member]" } } }, "localname": "BusinessCombinationMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ProposedPublicOfferingDetails" ], "xbrltype": "domainItemType" }, "cmlt_BusinessCombinationTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BusinessCombinationTerm", "terseLabel": "Business combination term" } } }, "localname": "BusinessCombinationTerm", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "durationItemType" }, "cmlt_BusinessCombinationsHavingAnAggregateFairMarketPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of fair market interests acquired at the acquisition date in the business combination.", "label": "BusinessCombinationsHavingAnAggregateFairMarketPercentage", "terseLabel": "Percentage of fair market value interest" } } }, "localname": "BusinessCombinationsHavingAnAggregateFairMarketPercentage", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "percentItemType" }, "cmlt_CMLSHoldingsIIILLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CMLSHoldingsIIILLCMember", "netLabel": "CMLS holdings III LLC [Member]", "terseLabel": "CMLS Holdings III LLC [Member]", "verboseLabel": "CMLS /holdings III LLC [Member]" } } }, "localname": "CMLSHoldingsIIILLCMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "domainItemType" }, "cmlt_CStoneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CStoneMember", "terseLabel": "CStone [Member]" } } }, "localname": "CStoneMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/LicenseAgreementsDetails", "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborationsDetails" ], "xbrltype": "domainItemType" }, "cmlt_CapitalizedWebsiteDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CapitalizedWebsiteDevelopmentMember", "terseLabel": "Capitalized Website Development [Member]" } } }, "localname": "CapitalizedWebsiteDevelopmentMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "cmlt_CarryingValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "CarryingValue", "terseLabel": "Carrying Value" } } }, "localname": "CarryingValue", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoftablesummarizetheCompanysoutstandingConvertiblePreferredStockTable" ], "xbrltype": "monetaryItemType" }, "cmlt_CashCashEquivalentsandRestrictedCashDetailsScheduleofcondensedconsolidatedstatementsofcashflowsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents and Restricted Cash (Details) - Schedule of condensed consolidated statements of cash flows [Line Items]" } } }, "localname": "CashCashEquivalentsandRestrictedCashDetailsScheduleofcondensedconsolidatedstatementsofcashflowsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofcondensedconsolidatedstatementsofcashflowsTable" ], "xbrltype": "stringItemType" }, "cmlt_CashCashEquivalentsandRestrictedCashDetailsScheduleofcondensedconsolidatedstatementsofcashflowsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents and Restricted Cash (Details) - Schedule of condensed consolidated statements of cash flows [Table]" } } }, "localname": "CashCashEquivalentsandRestrictedCashDetailsScheduleofcondensedconsolidatedstatementsofcashflowsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofcondensedconsolidatedstatementsofcashflowsTable" ], "xbrltype": "stringItemType" }, "cmlt_CashCashEquivalentsandRestrictedCashLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents and Restricted Cash [Line Items]" } } }, "localname": "CashCashEquivalentsandRestrictedCashLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/CashCashEquivalentsandRestrictedCash" ], "xbrltype": "stringItemType" }, "cmlt_CashCashEquivalentsandRestrictedCashTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents and Restricted Cash [Table]" } } }, "localname": "CashCashEquivalentsandRestrictedCashTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/CashCashEquivalentsandRestrictedCash" ], "xbrltype": "stringItemType" }, "cmlt_CashCashEquivalentsandRestrictedCashTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents and Restricted Cash (Tables) [Line Items]" } } }, "localname": "CashCashEquivalentsandRestrictedCashTablesLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/CashCashEquivalentsandRestrictedCashTables" ], "xbrltype": "stringItemType" }, "cmlt_CashCashEquivalentsandRestrictedCashTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents and Restricted Cash (Tables) [Table]" } } }, "localname": "CashCashEquivalentsandRestrictedCashTablesTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/CashCashEquivalentsandRestrictedCashTables" ], "xbrltype": "stringItemType" }, "cmlt_CashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CashEquivalentsAbstract", "terseLabel": "Cash equivalents:" } } }, "localname": "CashEquivalentsAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable0" ], "xbrltype": "stringItemType" }, "cmlt_CashEquivalentsAbstract00": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CashEquivalentsAbstract00", "terseLabel": "Cash equivalents:" } } }, "localname": "CashEquivalentsAbstract00", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsTable" ], "xbrltype": "stringItemType" }, "cmlt_ChangeInFairValueOfConvertiblePromissoryNotes": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Change in fair value of convertible promissory notes.", "label": "ChangeInFairValueOfConvertiblePromissoryNotes", "terseLabel": "Change in fair value of convertible promissory notes" } } }, "localname": "ChangeInFairValueOfConvertiblePromissoryNotes", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofnoprovisionforincometaxesTable" ], "xbrltype": "percentItemType" }, "cmlt_ChangeInFairValueOfWarrantLiabilites": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "ChangeInFairValueOfWarrantLiabilites", "label": "ChangeInFairValueOfWarrantLiabilites", "terseLabel": "Change in fair value of warrant liabilities" } } }, "localname": "ChangeInFairValueOfWarrantLiabilites", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofderivativewarrantliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "cmlt_ChangeInFairValuesOfConvertiblePromissoryNotes": { "auth_ref": [], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Change in fair values of convertible promissory notes.", "label": "ChangeInFairValuesOfConvertiblePromissoryNotes", "negatedLabel": "Change in fair value of convertible promissory notes" } } }, "localname": "ChangeInFairValuesOfConvertiblePromissoryNotes", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "cmlt_ChangeInValueOfSubjectToPossibleRedemption": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in value of Class A common stock subject to possible redemption.", "label": "ChangeInValueOfSubjectToPossibleRedemption", "terseLabel": "Change in value of Class A common stock subject to possible redemption" } } }, "localname": "ChangeInValueOfSubjectToPossibleRedemption", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "cmlt_CloudComputingArrangementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for Cloud Computing Arrangements.", "label": "CloudComputingArrangementsPolicyPolicyTextBlock", "terseLabel": "Cloud Computing Arrangements" } } }, "localname": "CloudComputingArrangementsPolicyPolicyTextBlock", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "cmlt_CollaborativeArrangementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for Collaborative Arrangements.", "label": "CollaborativeArrangementsPolicyPolicyTextBlock", "terseLabel": "Collaborative Arrangements" } } }, "localname": "CollaborativeArrangementsPolicyPolicyTextBlock", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "cmlt_CommercialBondsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CommercialBondsMember", "terseLabel": "Commercial bonds [Member]", "verboseLabel": "Commercial Bonds (Due within 90 Days) [Member]" } } }, "localname": "CommercialBondsMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable0", "http://cmlifesciencesspac.com/role/ScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsTable" ], "xbrltype": "domainItemType" }, "cmlt_CommitmentandContingenciesDetailsScheduleofleasecostsintheCompanyscondensedconsolidatedstatementsofoperationsandcomprehensivelossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitment and Contingencies (Details) - Schedule of lease costs in the Company\u2019s condensed consolidated statements of operations and comprehensive loss [Line Items]" } } }, "localname": "CommitmentandContingenciesDetailsScheduleofleasecostsintheCompanyscondensedconsolidatedstatementsofoperationsandcomprehensivelossLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofleasecostsintheCompanyscondensedconsolidatedstatementsofoperationsandcomprehensivelossTable" ], "xbrltype": "stringItemType" }, "cmlt_CommitmentandContingenciesDetailsScheduleofleasecostsintheCompanyscondensedconsolidatedstatementsofoperationsandcomprehensivelossTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitment and Contingencies (Details) - Schedule of lease costs in the Company\u2019s condensed consolidated statements of operations and comprehensive loss [Table]" } } }, "localname": "CommitmentandContingenciesDetailsScheduleofleasecostsintheCompanyscondensedconsolidatedstatementsofoperationsandcomprehensivelossTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofleasecostsintheCompanyscondensedconsolidatedstatementsofoperationsandcomprehensivelossTable" ], "xbrltype": "stringItemType" }, "cmlt_CommitmentandContingenciesDetailsScheduleofoperationsandcomprehensivelossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitment and Contingencies (Details) - Schedule of operations and comprehensive loss [Line Items]" } } }, "localname": "CommitmentandContingenciesDetailsScheduleofoperationsandcomprehensivelossLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofoperationsandcomprehensivelossTable" ], "xbrltype": "stringItemType" }, "cmlt_CommitmentandContingenciesDetailsScheduleofoperationsandcomprehensivelossTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitment and Contingencies (Details) - Schedule of operations and comprehensive loss [Table]" } } }, "localname": "CommitmentandContingenciesDetailsScheduleofoperationsandcomprehensivelossTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofoperationsandcomprehensivelossTable" ], "xbrltype": "stringItemType" }, "cmlt_CommitmentandContingenciesTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitment and Contingencies (Tables) [Line Items]" } } }, "localname": "CommitmentandContingenciesTablesLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentandContingenciesTables", "http://cmlifesciencesspac.com/role/CommitmentandContingenciesTables0" ], "xbrltype": "stringItemType" }, "cmlt_CommitmentandContingenciesTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitment and Contingencies (Tables) [Table]" } } }, "localname": "CommitmentandContingenciesTablesTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentandContingenciesTables", "http://cmlifesciencesspac.com/role/CommitmentandContingenciesTables0" ], "xbrltype": "stringItemType" }, "cmlt_CommitmentsandContingenciesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Line Items]" } } }, "localname": "CommitmentsandContingenciesDetailsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "cmlt_CommitmentsandContingenciesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Table]" } } }, "localname": "CommitmentsandContingenciesDetailsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "cmlt_CommitmentsandContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Line Items]" } } }, "localname": "CommitmentsandContingenciesLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingencies" ], "xbrltype": "stringItemType" }, "cmlt_CommitmentsandContingenciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Table]" } } }, "localname": "CommitmentsandContingenciesTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingencies" ], "xbrltype": "stringItemType" }, "cmlt_CommonStockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Abstract]" } } }, "localname": "CommonStockAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_CommonStockDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock (Details) [Line Items]" } } }, "localname": "CommonStockDetailsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/CommonStockDetails" ], "xbrltype": "stringItemType" }, "cmlt_CommonStockDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock (Details) [Table]" } } }, "localname": "CommonStockDetailsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/CommonStockDetails" ], "xbrltype": "stringItemType" }, "cmlt_CommonStockIssuedSharesSold": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CommonStockIssuedSharesSold", "terseLabel": "Common stock issued shares sold" } } }, "localname": "CommonStockIssuedSharesSold", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/CommonStockDetails" ], "xbrltype": "sharesItemType" }, "cmlt_CommonStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Line Items]" } } }, "localname": "CommonStockLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/CommonStock" ], "xbrltype": "stringItemType" }, "cmlt_CommonStockOutstandingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock outstanding, percentage.", "label": "CommonStockOutstandingPercentage", "terseLabel": "Converted basis, percentage" } } }, "localname": "CommonStockOutstandingPercentage", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "cmlt_CommonStockSharesSubjectToPossibleRedemption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock, shares subject to possible redemption.", "label": "CommonStockSharesSubjectToPossibleRedemption", "terseLabel": "Common stock, shares subject to possible redemption" } } }, "localname": "CommonStockSharesSubjectToPossibleRedemption", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "cmlt_CommonStockTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Table]" } } }, "localname": "CommonStockTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/CommonStock" ], "xbrltype": "stringItemType" }, "cmlt_CommonStockTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to common stock.", "label": "CommonStockTextBlock", "terseLabel": "COMMON STOCK" } } }, "localname": "CommonStockTextBlock", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/CommonStock" ], "xbrltype": "textBlockItemType" }, "cmlt_CommonStockValue1": { "auth_ref": [], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "CommonStockValue1", "terseLabel": "Class B common stock, $0.0001 par value; 20,000,000 shares authorized; 13,800,000 shares issued and outstanding" } } }, "localname": "CommonStockValue1", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "cmlt_CommonStockValueIssue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issue nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common share, par value and other disclosure concept are in another section within stockholders' equity.", "label": "CommonStockValueIssue", "terseLabel": "Conversion value" } } }, "localname": "CommonStockValueIssue", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_CommonStocksSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "CommonStocksSharesOutstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStocksSharesOutstanding", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/CommonStockDetails" ], "xbrltype": "sharesItemType" }, "cmlt_ConsultingFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of consulting fees.", "label": "ConsultingFees", "terseLabel": "Accrued consulting" } } }, "localname": "ConsultingFees", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofaccruedexpensesTable", "http://cmlifesciencesspac.com/role/ScheduleofaccruedexpensesTable0" ], "xbrltype": "monetaryItemType" }, "cmlt_ConversionPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ConversionPricePerShare", "terseLabel": "Conversion price (in Dollars per share)" } } }, "localname": "ConversionPricePerShare", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "perShareItemType" }, "cmlt_ConvertiblePreferredShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "ConvertiblePreferredShares", "terseLabel": "Convertible preferred shares" } } }, "localname": "ConvertiblePreferredShares", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofconvertiblepreferredstockoptionstopurchasecommonstockandunvestedrestrictedstockTable" ], "xbrltype": "sharesItemType" }, "cmlt_ConvertiblePreferredStockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock [Abstract]" } } }, "localname": "ConvertiblePreferredStockAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_ConvertiblePreferredStockDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock (Details) [Line Items]" } } }, "localname": "ConvertiblePreferredStockDetailsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "stringItemType" }, "cmlt_ConvertiblePreferredStockDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock (Details) [Table]" } } }, "localname": "ConvertiblePreferredStockDetailsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "stringItemType" }, "cmlt_ConvertiblePreferredStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock [Line Items]" } } }, "localname": "ConvertiblePreferredStockLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePreferredStock" ], "xbrltype": "stringItemType" }, "cmlt_ConvertiblePreferredStockTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock [Table]" } } }, "localname": "ConvertiblePreferredStockTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePreferredStock" ], "xbrltype": "stringItemType" }, "cmlt_ConvertiblePreferredStockTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock (Tables) [Line Items]" } } }, "localname": "ConvertiblePreferredStockTablesLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockTables", "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockTables0" ], "xbrltype": "stringItemType" }, "cmlt_ConvertiblePreferredStockTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock (Tables) [Table]" } } }, "localname": "ConvertiblePreferredStockTablesTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockTables", "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockTables0" ], "xbrltype": "stringItemType" }, "cmlt_ConvertiblePreferredStockTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ConvertiblePreferredStockTextBlock", "terseLabel": "CONVERTIBLE PREFERRED STOCK" } } }, "localname": "ConvertiblePreferredStockTextBlock", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePreferredStock" ], "xbrltype": "textBlockItemType" }, "cmlt_ConvertiblePromissoryNotesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Promissory Notes (Details) [Line Items]" } } }, "localname": "ConvertiblePromissoryNotesDetailsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePromissoryNotesDetails" ], "xbrltype": "stringItemType" }, "cmlt_ConvertiblePromissoryNotesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Promissory Notes (Details) [Table]" } } }, "localname": "ConvertiblePromissoryNotesDetailsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePromissoryNotesDetails" ], "xbrltype": "stringItemType" }, "cmlt_ConvertiblePromissoryNotesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Promissory Notes [Line Items]" } } }, "localname": "ConvertiblePromissoryNotesLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePromissoryNotes" ], "xbrltype": "stringItemType" }, "cmlt_ConvertiblePromissoryNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ConvertiblePromissoryNotesMember", "terseLabel": "Convertible Promissory Notes [Member]" } } }, "localname": "ConvertiblePromissoryNotesMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsTable" ], "xbrltype": "domainItemType" }, "cmlt_ConvertiblePromissoryNotesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Promissory Notes [Table]" } } }, "localname": "ConvertiblePromissoryNotesTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePromissoryNotes" ], "xbrltype": "stringItemType" }, "cmlt_DeferredOfferingCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Offering Costs Policy Text Block.", "label": "DeferredOfferingCostsPolicyTextBlock", "terseLabel": "Offering Costs Associated with the Initial Public Offering" } } }, "localname": "DeferredOfferingCostsPolicyTextBlock", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "cmlt_DeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DeferredTaxAssetsAbstract", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofnetdeferredtaxassetsTable" ], "xbrltype": "stringItemType" }, "cmlt_DeferredUnderwritingCommission": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Underwriting Commission", "label": "DeferredUnderwritingCommission", "terseLabel": "Deferred Underwriting Commission" } } }, "localname": "DeferredUnderwritingCommission", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/InitialPublicOfferingDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_DenominatorWeightedAverageClassACommonStockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DenominatorWeightedAverageClassACommonStockAbstract", "terseLabel": "Denominator: Weighted average Class A common stock" } } }, "localname": "DenominatorWeightedAverageClassACommonStockAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofbasicanddilutednetincomelosspercommonshareTable" ], "xbrltype": "stringItemType" }, "cmlt_DerivativeWarrantLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DerivativeWarrantLiabilitiesAbstract", "terseLabel": "Derivative Warrant Liabilities:" } } }, "localname": "DerivativeWarrantLiabilitiesAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "stringItemType" }, "cmlt_DerivativeWarrantLiabilitiesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Warrant Liabilities (Details) [Line Items]" } } }, "localname": "DerivativeWarrantLiabilitiesDetailsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DerivativeWarrantLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "cmlt_DerivativeWarrantLiabilitiesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Warrant Liabilities (Details) [Table]" } } }, "localname": "DerivativeWarrantLiabilitiesDetailsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DerivativeWarrantLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "cmlt_DescriptionOfBusinessCombinationConsideration": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination Consideration, description.", "label": "DescriptionOfBusinessCombinationConsideration", "terseLabel": "Business Combination Consideration, description" } } }, "localname": "DescriptionOfBusinessCombinationConsideration", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "stringItemType" }, "cmlt_DescriptionOfInitialPublicOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DescriptionOfInitialPublicOffering", "terseLabel": "Initial public offering, description" } } }, "localname": "DescriptionOfInitialPublicOffering", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/InitialPublicOfferingDetails" ], "xbrltype": "stringItemType" }, "cmlt_DescriptionOfPurchaseAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of the Purchase agreement.", "label": "DescriptionOfPurchaseAgreement", "terseLabel": "Purchase agreement, description" } } }, "localname": "DescriptionOfPurchaseAgreement", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "cmlt_DescriptionofOrganizationandBusinessOperationsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of Organization and Business Operations (Details) [Line Items]" } } }, "localname": "DescriptionofOrganizationandBusinessOperationsDetailsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "stringItemType" }, "cmlt_DescriptionofOrganizationandBusinessOperationsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of Organization and Business Operations (Details) [Table]" } } }, "localname": "DescriptionofOrganizationandBusinessOperationsDetailsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "stringItemType" }, "cmlt_DevelopmentAndRegulatoryMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Development and regulatory milestone payments.", "label": "DevelopmentAndRegulatoryMilestonePayments", "terseLabel": "Development and regulatory milestone payments" } } }, "localname": "DevelopmentAndRegulatoryMilestonePayments", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/LicenseAgreementsDetails", "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborationsDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_DevelopmentMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Development milestone payments.", "label": "DevelopmentMilestonePayments", "terseLabel": "Development milestone payments" } } }, "localname": "DevelopmentMilestonePayments", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/LicenseAgreementsDetails", "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborationsDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_DissolutionExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "DissolutionExpenses", "terseLabel": "Dissolution expenses" } } }, "localname": "DissolutionExpenses", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_DrRobinsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DrRobinsMember", "terseLabel": "Dr. Robins [Member]" } } }, "localname": "DrRobinsMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "cmlt_EQRxINCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EQRxINCMember", "terseLabel": "EQRx, INC.", "verboseLabel": "EQRx, INC. [Member]" } } }, "localname": "EQRxINCMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy", "http://cmlifesciencesspac.com/role/AccruedExpenses", "http://cmlifesciencesspac.com/role/AccruedExpensesTables", "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies", "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails", "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables", "http://cmlifesciencesspac.com/role/CashCashEquivalentsandRestrictedCash", "http://cmlifesciencesspac.com/role/CashCashEquivalentsandRestrictedCashTables", "http://cmlifesciencesspac.com/role/CommitmentandContingenciesTables", "http://cmlifesciencesspac.com/role/CommitmentandContingenciesTables0", "http://cmlifesciencesspac.com/role/CommitmentsandContingencies", "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails", "http://cmlifesciencesspac.com/role/CommonStock", "http://cmlifesciencesspac.com/role/CommonStockDetails", "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet", "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow", "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement", "http://cmlifesciencesspac.com/role/ConvertiblePreferredStock", "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails", "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockTables", "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockTables0", "http://cmlifesciencesspac.com/role/ConvertiblePromissoryNotes", "http://cmlifesciencesspac.com/role/ConvertiblePromissoryNotesDetails", "http://cmlifesciencesspac.com/role/EmployeeBenefits", "http://cmlifesciencesspac.com/role/EmployeeBenefitsDetails", "http://cmlifesciencesspac.com/role/FairValueMeasurements", "http://cmlifesciencesspac.com/role/FairValueMeasurementsTables", "http://cmlifesciencesspac.com/role/IncomeTaxes", "http://cmlifesciencesspac.com/role/IncomeTaxesDetails", "http://cmlifesciencesspac.com/role/IncomeTaxesTables", "http://cmlifesciencesspac.com/role/LicenseAgreements", "http://cmlifesciencesspac.com/role/LicenseAgreementsDetails", "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborations", "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborationsDetails", "http://cmlifesciencesspac.com/role/NatureofBusiness", "http://cmlifesciencesspac.com/role/NatureofBusinessDetails", "http://cmlifesciencesspac.com/role/NetLossPerShare", "http://cmlifesciencesspac.com/role/NetLossPerShareTables", "http://cmlifesciencesspac.com/role/PropertyandEquipmentNet", "http://cmlifesciencesspac.com/role/PropertyandEquipmentNetDetails", "http://cmlifesciencesspac.com/role/PropertyandEquipmentNetTables", "http://cmlifesciencesspac.com/role/ScheduleofaccruedexpensesTable", "http://cmlifesciencesspac.com/role/ScheduleofaccruedexpensesTable0", "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable0", "http://cmlifesciencesspac.com/role/ScheduleofcomputationofbasicanddilutednetlosspershareTable", "http://cmlifesciencesspac.com/role/ScheduleofcomputationofbasicanddilutednetlosspershareTable0", "http://cmlifesciencesspac.com/role/ScheduleofcondensedconsolidatedstatementsofcashflowsTable", "http://cmlifesciencesspac.com/role/ScheduleofconsolidatedstatementofcashflowsTable", "http://cmlifesciencesspac.com/role/ScheduleofconvertiblepreferredstockoptionstopurchasecommonstockandunvestedrestrictedstockTable", "http://cmlifesciencesspac.com/role/ScheduleofconvertiblepreferredstockoptionstopurchasecommonstockandunvestedrestrictedstockTable0", "http://cmlifesciencesspac.com/role/ScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsTable", "http://cmlifesciencesspac.com/role/ScheduleofleasecostsintheCompanyscondensedconsolidatedstatementsofoperationsandcomprehensivelossTable", "http://cmlifesciencesspac.com/role/ScheduleofnetdeferredtaxassetsTable", "http://cmlifesciencesspac.com/role/ScheduleofnoprovisionforincometaxesTable", "http://cmlifesciencesspac.com/role/ScheduleofoutstandingConvertiblePreferredStockTable", "http://cmlifesciencesspac.com/role/ScheduleofpropertyandequipmentnetTable", "http://cmlifesciencesspac.com/role/ScheduleofpropertyplantandequipmentTable", "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable", "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable0", "http://cmlifesciencesspac.com/role/ScheduleofstockbasedcompensationexpenseTable", "http://cmlifesciencesspac.com/role/ScheduleofstockbasedcompensationexpenseTable0", "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable", "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable0", "http://cmlifesciencesspac.com/role/ScheduleoftablesummarizetheCompanysoutstandingConvertiblePreferredStockTable", "http://cmlifesciencesspac.com/role/ScheduleofweightedaverageassumptionTable", "http://cmlifesciencesspac.com/role/ScheduleofweightedaverageassumptionsTable", "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3", "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3_Parentheticals", "http://cmlifesciencesspac.com/role/StockBasedCompensation", "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails", "http://cmlifesciencesspac.com/role/StockBasedCompensationTables", "http://cmlifesciencesspac.com/role/StockholdersEquity", "http://cmlifesciencesspac.com/role/StockholdersEquityDetails", "http://cmlifesciencesspac.com/role/SubsequentEvents", "http://cmlifesciencesspac.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "cmlt_EmergingGrowthCompanyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Emerging Growth Company Status Policy Text Block.", "label": "EmergingGrowthCompanyPolicyTextBlock", "terseLabel": "Emerging Growth Company Status" } } }, "localname": "EmergingGrowthCompanyPolicyTextBlock", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "cmlt_EmployeeBenefitsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Benefits [Abstract]" } } }, "localname": "EmployeeBenefitsAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_EmployeeBenefitsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Benefits (Details) [Line Items]" } } }, "localname": "EmployeeBenefitsDetailsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/EmployeeBenefitsDetails" ], "xbrltype": "stringItemType" }, "cmlt_EmployeeBenefitsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Benefits (Details) [Table]" } } }, "localname": "EmployeeBenefitsDetailsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/EmployeeBenefitsDetails" ], "xbrltype": "stringItemType" }, "cmlt_EmployeeBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Benefits [Line Items]" } } }, "localname": "EmployeeBenefitsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/EmployeeBenefits" ], "xbrltype": "stringItemType" }, "cmlt_EmployeeBenefitsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Benefits [Table]" } } }, "localname": "EmployeeBenefitsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/EmployeeBenefits" ], "xbrltype": "stringItemType" }, "cmlt_EmployeeBenefitsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EmployeeBenefitsTextBlock", "terseLabel": "EMPLOYEE BENEFITS" } } }, "localname": "EmployeeBenefitsTextBlock", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/EmployeeBenefits" ], "xbrltype": "textBlockItemType" }, "cmlt_EstimatedUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Estimated useful life.", "label": "EstimatedUsefulLife", "terseLabel": "Estimated Useful Life" } } }, "localname": "EstimatedUsefulLife", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "stringItemType" }, "cmlt_ExercisablePriceOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ExercisablePriceOfWarrants", "terseLabel": "Price of private placement warrant (in Dollars per share)" } } }, "localname": "ExercisablePriceOfWarrants", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "perShareItemType" }, "cmlt_ExercisePriceEighteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ExercisePriceEighteenMember", "terseLabel": "Exercise price 18.00 [Member]" } } }, "localname": "ExercisePriceEighteenMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "cmlt_ExercisePriceTenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ExercisePriceTenMember", "terseLabel": "Exercise price 10.00 [Member]" } } }, "localname": "ExercisePriceTenMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "cmlt_ExternalResearchAndDevelopment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of accrued research and development fees.", "label": "ExternalResearchAndDevelopment", "terseLabel": "External research and development" } } }, "localname": "ExternalResearchAndDevelopment", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofaccruedexpensesTable", "http://cmlifesciencesspac.com/role/ScheduleofaccruedexpensesTable0" ], "xbrltype": "monetaryItemType" }, "cmlt_FairValueLevelDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FairValueLevelDescription", "terseLabel": "Fair Value Level" } } }, "localname": "FairValueLevelDescription", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable0" ], "xbrltype": "stringItemType" }, "cmlt_FairValueMeasurementsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements (Details) [Line Items]" } } }, "localname": "FairValueMeasurementsDetailsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "cmlt_FairValueMeasurementsDetailsScheduleofprovidesquantitativeinformationregardingLevel3fairvaluemeasurementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements (Details) - Schedule of provides quantitative information regarding Level 3 fair value measurements [Line Items]" } } }, "localname": "FairValueMeasurementsDetailsScheduleofprovidesquantitativeinformationregardingLevel3fairvaluemeasurementsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofprovidesquantitativeinformationregardingLevel3fairvaluemeasurementsTable" ], "xbrltype": "stringItemType" }, "cmlt_FairValueMeasurementsDetailsScheduleofprovidesquantitativeinformationregardingLevel3fairvaluemeasurementsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements (Details) - Schedule of provides quantitative information regarding Level 3 fair value measurements [Table]" } } }, "localname": "FairValueMeasurementsDetailsScheduleofprovidesquantitativeinformationregardingLevel3fairvaluemeasurementsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofprovidesquantitativeinformationregardingLevel3fairvaluemeasurementsTable" ], "xbrltype": "stringItemType" }, "cmlt_FairValueMeasurementsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements (Details) [Table]" } } }, "localname": "FairValueMeasurementsDetailsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "cmlt_FairValueMeasurementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements [Line Items]" } } }, "localname": "FairValueMeasurementsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/FairValueMeasurements" ], "xbrltype": "stringItemType" }, "cmlt_FairValueMeasurementsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements [Table]" } } }, "localname": "FairValueMeasurementsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/FairValueMeasurements" ], "xbrltype": "stringItemType" }, "cmlt_FairValueMeasurementsTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements (Tables) [Line Items]" } } }, "localname": "FairValueMeasurementsTablesLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/FairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "cmlt_FairValueMeasurementsTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements (Tables) [Table]" } } }, "localname": "FairValueMeasurementsTablesTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/FairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "cmlt_FairValueOfRestrictedStockGrant": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "FairValueOfRestrictedStockGrant", "terseLabel": "Fair value of restricted stock grant (in Dollars)" } } }, "localname": "FairValueOfRestrictedStockGrant", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_FederalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FederalMember", "terseLabel": "Federal [Member]" } } }, "localname": "FederalMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "cmlt_FinancialLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FinancialLiabilitiesAbstract", "terseLabel": "Financial liabilities" } } }, "localname": "FinancialLiabilitiesAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsTable" ], "xbrltype": "stringItemType" }, "cmlt_FinancialLiabilitiesFairValueAggregateFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of Financial liabilities fair value aggregate fair value.", "label": "FinancialLiabilitiesFairValueAggregateFairValue", "terseLabel": "Aggregate FairValue" } } }, "localname": "FinancialLiabilitiesFairValueAggregateFairValue", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsTable" ], "xbrltype": "monetaryItemType" }, "cmlt_FinancialLiabilitiesFairValueAmortizedCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of Financial liabilities fair value amortized costs.", "label": "FinancialLiabilitiesFairValueAmortizedCosts", "terseLabel": "Amortized Costs" } } }, "localname": "FinancialLiabilitiesFairValueAmortizedCosts", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsTable" ], "xbrltype": "monetaryItemType" }, "cmlt_FinancialLiabilitiesFairValueGrossUnrealizedGain": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of financial liabilities fair value gross unrealized gain.", "label": "FinancialLiabilitiesFairValueGrossUnrealizedGain", "terseLabel": "Gross Unrealized Gain" } } }, "localname": "FinancialLiabilitiesFairValueGrossUnrealizedGain", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsTable" ], "xbrltype": "monetaryItemType" }, "cmlt_FinancialLiabilitiesFairValueGrossUnrealizedLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of financial liabilities fair value gross unrealized loss.", "label": "FinancialLiabilitiesFairValueGrossUnrealizedLoss", "terseLabel": "Gross Unrealized Loss" } } }, "localname": "FinancialLiabilitiesFairValueGrossUnrealizedLoss", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsTable" ], "xbrltype": "monetaryItemType" }, "cmlt_FoodAndDrugAdministration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Food and drug administration.", "label": "FoodAndDrugAdministration", "terseLabel": "Food and drug administration" } } }, "localname": "FoodAndDrugAdministration", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/LicenseAgreementsDetails", "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborationsDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_FounderPurchaseSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FounderPurchaseSharesMember", "terseLabel": "Founder Purchase Shares [Member]" } } }, "localname": "FounderPurchaseSharesMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "cmlt_FounderSharesDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Founder shares description.", "label": "FounderSharesDescription", "terseLabel": "Founder shares, description" } } }, "localname": "FounderSharesDescription", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "cmlt_FounderSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FounderSharesMember", "terseLabel": "Founder Shares [Member]" } } }, "localname": "FounderSharesMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "cmlt_FranchiseTaxPayable": { "auth_ref": [], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of franchise tax payable.", "label": "FranchiseTaxPayable", "terseLabel": "Franchise tax payable" } } }, "localname": "FranchiseTaxPayable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "cmlt_GeneratingProceeds": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "GeneratingProceeds", "terseLabel": "Generating proceeds" } } }, "localname": "GeneratingProceeds", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_GrossProceeds": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gross proceeds.", "label": "GrossProceeds", "netLabel": "Gross proceeds (in Dollars)", "terseLabel": "Gross proceeds", "verboseLabel": "Gross Proceeds" } } }, "localname": "GrossProceeds", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails", "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://cmlifesciencesspac.com/role/InitialPublicOfferingDetails", "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_GrossUnrealizedGain": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gross unrealized gain.", "label": "GrossUnrealizedGain", "terseLabel": "Gross Unrealized Gain" } } }, "localname": "GrossUnrealizedGain", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable0" ], "xbrltype": "monetaryItemType" }, "cmlt_GrossUnrealizedLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross unrealized loss.", "label": "GrossUnrealizedLoss", "terseLabel": "Gross Unrealized Loss" } } }, "localname": "GrossUnrealizedLoss", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable0" ], "xbrltype": "monetaryItemType" }, "cmlt_IncomeFromInvestmentsHeldInTrustAccount": { "auth_ref": [], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "IncomeFromInvestmentsHeldInTrustAccount", "terseLabel": "Income from investments held in Trust Account" } } }, "localname": "IncomeFromInvestmentsHeldInTrustAccount", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement", "http://cmlifesciencesspac.com/role/ScheduleofbasicanddilutednetincomelosspercommonshareTable" ], "xbrltype": "monetaryItemType" }, "cmlt_IncomeTaxesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) [Line Items]" } } }, "localname": "IncomeTaxesDetailsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "cmlt_IncomeTaxesDetailsScheduleofnetdeferredtaxassetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) - Schedule of net deferred tax assets [Line Items]" } } }, "localname": "IncomeTaxesDetailsScheduleofnetdeferredtaxassetsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofnetdeferredtaxassetsTable" ], "xbrltype": "stringItemType" }, "cmlt_IncomeTaxesDetailsScheduleofnetdeferredtaxassetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) - Schedule of net deferred tax assets [Table]" } } }, "localname": "IncomeTaxesDetailsScheduleofnetdeferredtaxassetsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofnetdeferredtaxassetsTable" ], "xbrltype": "stringItemType" }, "cmlt_IncomeTaxesDetailsScheduleofnoprovisionforincometaxesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) - Schedule of no provision for income taxes [Line Items]" } } }, "localname": "IncomeTaxesDetailsScheduleofnoprovisionforincometaxesLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofnoprovisionforincometaxesTable" ], "xbrltype": "stringItemType" }, "cmlt_IncomeTaxesDetailsScheduleofnoprovisionforincometaxesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) - Schedule of no provision for income taxes [Table]" } } }, "localname": "IncomeTaxesDetailsScheduleofnoprovisionforincometaxesTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofnoprovisionforincometaxesTable" ], "xbrltype": "stringItemType" }, "cmlt_IncomeTaxesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) [Table]" } } }, "localname": "IncomeTaxesDetailsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "cmlt_IncomeTaxesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes [Line Items]" } } }, "localname": "IncomeTaxesLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/IncomeTaxes" ], "xbrltype": "stringItemType" }, "cmlt_IncomeTaxesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes [Table]" } } }, "localname": "IncomeTaxesTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/IncomeTaxes" ], "xbrltype": "stringItemType" }, "cmlt_IncomeTaxesTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Tables) [Line Items]" } } }, "localname": "IncomeTaxesTablesLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/IncomeTaxesTables" ], "xbrltype": "stringItemType" }, "cmlt_IncomeTaxesTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Tables) [Table]" } } }, "localname": "IncomeTaxesTablesTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/IncomeTaxesTables" ], "xbrltype": "stringItemType" }, "cmlt_IncurringOfferingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "IncurringOfferingCosts", "terseLabel": "Incurring offering costs" } } }, "localname": "IncurringOfferingCosts", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_InitialFairValueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "InitialFairValueMember", "terseLabel": "Initial Fair Value [Member]" } } }, "localname": "InitialFairValueMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofprovidesquantitativeinformationregardingLevel3fairvaluemeasurementsTable" ], "xbrltype": "domainItemType" }, "cmlt_InitialPublicOfferingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Initial Public Offering [Abstract]" } } }, "localname": "InitialPublicOfferingAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_InitialPublicOfferingDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Initial Public Offering (Details) [Line Items]" } } }, "localname": "InitialPublicOfferingDetailsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/InitialPublicOfferingDetails" ], "xbrltype": "stringItemType" }, "cmlt_InitialPublicOfferingDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Initial Public Offering (Details) [Table]" } } }, "localname": "InitialPublicOfferingDetailsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/InitialPublicOfferingDetails" ], "xbrltype": "stringItemType" }, "cmlt_InitialPublicOfferingTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial Public Offering.", "label": "InitialPublicOfferingTextBlock", "terseLabel": "Initial Public Offering" } } }, "localname": "InitialPublicOfferingTextBlock", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/InitialPublicOffering" ], "xbrltype": "textBlockItemType" }, "cmlt_InitialValueOfSubjectToPossibleRedemption": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "InitialValueOfSubjectToPossibleRedemption.", "label": "InitialValueOfSubjectToPossibleRedemption", "terseLabel": "Initial value of Class A common stock subject to possible redemption" } } }, "localname": "InitialValueOfSubjectToPossibleRedemption", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "cmlt_IssuanceCostsForConvertiblePreferredStockIncludedInAccountsPayableAndAccruedExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance costs for convertible preferred stock included in accounts payable and accrued expenses.", "label": "IssuanceCostsForConvertiblePreferredStockIncludedInAccountsPayableAndAccruedExpenses", "terseLabel": "Issuance costs for convertible preferred stock included in accounts payable and accrued expenses" } } }, "localname": "IssuanceCostsForConvertiblePreferredStockIncludedInAccountsPayableAndAccruedExpenses", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "cmlt_IssuanceResultingInAggregateProceeds": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "IssuanceResultingInAggregateProceeds", "terseLabel": "Issuance resulting in aggregate proceeds (in Dollars)" } } }, "localname": "IssuanceResultingInAggregateProceeds", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_IssuedAndOutstandingOrdinarySharesPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IssuedAndOutstandingOrdinarySharesPercentage", "terseLabel": "Issued and outstanding ordinary shares percentage" } } }, "localname": "IssuedAndOutstandingOrdinarySharesPercentage", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "cmlt_LeaseAgreementAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease agreement amount.", "label": "LeaseAgreementAmount", "terseLabel": "Lease agreement amount" } } }, "localname": "LeaseAgreementAmount", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_LicenseAgreementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License Agreements [Abstract]" } } }, "localname": "LicenseAgreementsAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_LicenseAgreementsAndDiscoveryCollaborationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License Agreements And Discovery Collaborations [Abstract]" } } }, "localname": "LicenseAgreementsAndDiscoveryCollaborationsAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_LicenseAgreementsAndDiscoveryCollaborationsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LicenseAgreementsAndDiscoveryCollaborationsTextBlock", "terseLabel": "LICENSE AGREEMENTS AND DISCOVERY COLLABORATIONS" } } }, "localname": "LicenseAgreementsAndDiscoveryCollaborationsTextBlock", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborations" ], "xbrltype": "textBlockItemType" }, "cmlt_LicenseAgreementsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License Agreements (Details) [Line Items]" } } }, "localname": "LicenseAgreementsDetailsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/LicenseAgreementsDetails" ], "xbrltype": "stringItemType" }, "cmlt_LicenseAgreementsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License Agreements (Details) [Table]" } } }, "localname": "LicenseAgreementsDetailsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/LicenseAgreementsDetails" ], "xbrltype": "stringItemType" }, "cmlt_LicenseAgreementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License Agreements [Line Items]" } } }, "localname": "LicenseAgreementsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/LicenseAgreements" ], "xbrltype": "stringItemType" }, "cmlt_LicenseAgreementsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License Agreements [Table]" } } }, "localname": "LicenseAgreementsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/LicenseAgreements" ], "xbrltype": "stringItemType" }, "cmlt_LicenseAgreementsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LicenseAgreementsTextBlock", "terseLabel": "LICENSE AGREEMENTS" } } }, "localname": "LicenseAgreementsTextBlock", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/LicenseAgreements" ], "xbrltype": "textBlockItemType" }, "cmlt_LicenseAgreementsandDiscoveryCollaborationsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License Agreements and Discovery Collaborations (Details) [Line Items]" } } }, "localname": "LicenseAgreementsandDiscoveryCollaborationsDetailsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborationsDetails" ], "xbrltype": "stringItemType" }, "cmlt_LicenseAgreementsandDiscoveryCollaborationsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License Agreements and Discovery Collaborations (Details) [Table]" } } }, "localname": "LicenseAgreementsandDiscoveryCollaborationsDetailsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborationsDetails" ], "xbrltype": "stringItemType" }, "cmlt_LicenseAgreementsandDiscoveryCollaborationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License Agreements and Discovery Collaborations [Line Items]" } } }, "localname": "LicenseAgreementsandDiscoveryCollaborationsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborations" ], "xbrltype": "stringItemType" }, "cmlt_LicenseAgreementsandDiscoveryCollaborationsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License Agreements and Discovery Collaborations [Table]" } } }, "localname": "LicenseAgreementsandDiscoveryCollaborationsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborations" ], "xbrltype": "stringItemType" }, "cmlt_LiquidationPreference": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Liquidation Preference.", "label": "LiquidationPreference", "terseLabel": "Liquidation Preference" } } }, "localname": "LiquidationPreference", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofoutstandingConvertiblePreferredStockTable", "http://cmlifesciencesspac.com/role/ScheduleoftablesummarizetheCompanysoutstandingConvertiblePreferredStockTable" ], "xbrltype": "monetaryItemType" }, "cmlt_LossUponIssuanceOfPrivatePlacementWarrants": { "auth_ref": [], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loss upon issuance of private placement warrants.", "label": "LossUponIssuanceOfPrivatePlacementWarrants", "terseLabel": "Loss upon issuance of private placement warrants" } } }, "localname": "LossUponIssuanceOfPrivatePlacementWarrants", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "cmlt_MrHenryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MrHenryMember", "terseLabel": "Mr. Henry [Member]" } } }, "localname": "MrHenryMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "cmlt_MrHenryMrRobinsAndDrRobinsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MrHenryMrRobinsAndDrRobinsMember", "terseLabel": "Mr. Henry, Mr. Robins and Dr. Robins [Member]" } } }, "localname": "MrHenryMrRobinsAndDrRobinsMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/PrivatePlacementDetails" ], "xbrltype": "domainItemType" }, "cmlt_MrOwusuKesseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MrOwusuKesseMember", "terseLabel": "Mr. Owusu-Kesse [Member]" } } }, "localname": "MrOwusuKesseMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/PrivatePlacementDetails", "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "cmlt_MrRobinsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MrRobinsMember", "terseLabel": "Mr. Robins [Member]" } } }, "localname": "MrRobinsMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "cmlt_NatureofBusinessDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nature of Business (Details) [Line Items]" } } }, "localname": "NatureofBusinessDetailsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/NatureofBusinessDetails" ], "xbrltype": "stringItemType" }, "cmlt_NatureofBusinessDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nature of Business (Details) [Table]" } } }, "localname": "NatureofBusinessDetailsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/NatureofBusinessDetails" ], "xbrltype": "stringItemType" }, "cmlt_NatureofBusinessLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nature of Business [Line Items]" } } }, "localname": "NatureofBusinessLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/NatureofBusiness" ], "xbrltype": "stringItemType" }, "cmlt_NatureofBusinessTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nature of Business [Table]" } } }, "localname": "NatureofBusinessTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/NatureofBusiness" ], "xbrltype": "stringItemType" }, "cmlt_NetLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "NetLoss", "terseLabel": "Net loss incurred by company" } } }, "localname": "NetLoss", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/NatureofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_NetLossPerShareBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NetLossPerShareBasicAndDiluted", "terseLabel": "Net loss per share, basic and diluted" } } }, "localname": "NetLossPerShareBasicAndDiluted", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofcomputationofbasicanddilutednetlosspershareTable", "http://cmlifesciencesspac.com/role/ScheduleofcomputationofbasicanddilutednetlosspershareTable0" ], "xbrltype": "perShareItemType" }, "cmlt_NetLossPerShareDetailsScheduleofcomputationofbasicanddilutednetlosspershareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss Per Share (Details) - Schedule of computation of basic and diluted net loss per share [Line Items]" } } }, "localname": "NetLossPerShareDetailsScheduleofcomputationofbasicanddilutednetlosspershareLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofcomputationofbasicanddilutednetlosspershareTable", "http://cmlifesciencesspac.com/role/ScheduleofcomputationofbasicanddilutednetlosspershareTable0" ], "xbrltype": "stringItemType" }, "cmlt_NetLossPerShareDetailsScheduleofcomputationofbasicanddilutednetlosspershareTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss Per Share (Details) - Schedule of computation of basic and diluted net loss per share [Table]" } } }, "localname": "NetLossPerShareDetailsScheduleofcomputationofbasicanddilutednetlosspershareTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofcomputationofbasicanddilutednetlosspershareTable", "http://cmlifesciencesspac.com/role/ScheduleofcomputationofbasicanddilutednetlosspershareTable0" ], "xbrltype": "stringItemType" }, "cmlt_NetLossPerShareDetailsScheduleofconvertiblepreferredstockoptionstopurchasecommonstockandunvestedrestrictedstockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss Per Share (Details) - Schedule of convertible preferred stock, options to purchase common stock and unvested restricted stock [Line Items]" } } }, "localname": "NetLossPerShareDetailsScheduleofconvertiblepreferredstockoptionstopurchasecommonstockandunvestedrestrictedstockLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofconvertiblepreferredstockoptionstopurchasecommonstockandunvestedrestrictedstockTable", "http://cmlifesciencesspac.com/role/ScheduleofconvertiblepreferredstockoptionstopurchasecommonstockandunvestedrestrictedstockTable0" ], "xbrltype": "stringItemType" }, "cmlt_NetLossPerShareDetailsScheduleofconvertiblepreferredstockoptionstopurchasecommonstockandunvestedrestrictedstockTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss Per Share (Details) - Schedule of convertible preferred stock, options to purchase common stock and unvested restricted stock [Table]" } } }, "localname": "NetLossPerShareDetailsScheduleofconvertiblepreferredstockoptionstopurchasecommonstockandunvestedrestrictedstockTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofconvertiblepreferredstockoptionstopurchasecommonstockandunvestedrestrictedstockTable", "http://cmlifesciencesspac.com/role/ScheduleofconvertiblepreferredstockoptionstopurchasecommonstockandunvestedrestrictedstockTable0" ], "xbrltype": "stringItemType" }, "cmlt_NetLossPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss Per Share [Line Items]" } } }, "localname": "NetLossPerShareLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/NetLossPerShare" ], "xbrltype": "stringItemType" }, "cmlt_NetLossPerShareTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss Per Share [Table]" } } }, "localname": "NetLossPerShareTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/NetLossPerShare" ], "xbrltype": "stringItemType" }, "cmlt_NetLossPerShareTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss Per Share (Tables) [Line Items]" } } }, "localname": "NetLossPerShareTablesLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/NetLossPerShareTables" ], "xbrltype": "stringItemType" }, "cmlt_NetLossPerShareTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss Per Share (Tables) [Table]" } } }, "localname": "NetLossPerShareTablesTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/NetLossPerShareTables" ], "xbrltype": "stringItemType" }, "cmlt_NetProceeds": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of net proceeds.", "label": "NetProceeds", "terseLabel": "Net proceeds (in Dollars)" } } }, "localname": "NetProceeds", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_NetTangibleAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Assets held from tangible.", "label": "NetTangibleAssets", "terseLabel": "Net tangible assets" } } }, "localname": "NetTangibleAssets", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_NoncreditablePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non-creditable payment.", "label": "NoncreditablePayment", "terseLabel": "Non-creditable payment" } } }, "localname": "NoncreditablePayment", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/LicenseAgreementsDetails", "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborationsDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_NumberOfSharesCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NumberOfSharesCommonStock", "terseLabel": "Number of shares common stock" } } }, "localname": "NumberOfSharesCommonStock", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "cmlt_NumeratorIncomeAllocableToClassACommonStockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NumeratorIncomeAllocableToClassACommonStockAbstract", "terseLabel": "Numerator: Income allocable to Class A common stock" } } }, "localname": "NumeratorIncomeAllocableToClassACommonStockAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofbasicanddilutednetincomelosspercommonshareTable" ], "xbrltype": "stringItemType" }, "cmlt_OfferingCostsIncludedInAccruedExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Offering costs included in accrued expenses.", "label": "OfferingCostsIncludedInAccruedExpenses", "terseLabel": "Offering costs included in accrued expenses" } } }, "localname": "OfferingCostsIncludedInAccruedExpenses", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "cmlt_OfferingCostsPaidByRelatedPartyUnderPromissoryNote": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "OfferingCostsPaidByRelatedPartyUnderPromissoryNote", "terseLabel": "Offering costs paid by related party under promissory note" } } }, "localname": "OfferingCostsPaidByRelatedPartyUnderPromissoryNote", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "cmlt_OfferingCostsPaidInExchangeForIssuance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Offering costs paid in exchange for issuance.", "label": "OfferingCostsPaidInExchangeForIssuance", "terseLabel": "Offering costs paid in exchange for issuance of Class B common stock to Sponsor" } } }, "localname": "OfferingCostsPaidInExchangeForIssuance", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "cmlt_OfferingCostsValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Offering costs.", "label": "OfferingCostsValue", "negatedLabel": "Offering costs" } } }, "localname": "OfferingCostsValue", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "cmlt_OperatingExpensesAbstract0": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OperatingExpensesAbstract0", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract0", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "cmlt_OperatingLeaseAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating lease asset.", "label": "OperatingLeaseAsset", "negatedLabel": "Operating lease asset" } } }, "localname": "OperatingLeaseAsset", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofnetdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "cmlt_OtherAssetNoncurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "OtherAssetNoncurrent", "terseLabel": "Other non-current assets" } } }, "localname": "OtherAssetNoncurrent", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborationsDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_OtherExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense classified as other.", "label": "OtherExpense", "terseLabel": "Other" } } }, "localname": "OtherExpense", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofaccruedexpensesTable", "http://cmlifesciencesspac.com/role/ScheduleofaccruedexpensesTable0" ], "xbrltype": "monetaryItemType" }, "cmlt_OtherResearchAndDevelopmentExpenses": { "auth_ref": [], "calculation": { "http://cmlifesciencesspac.com/role/ScheduleofstockbasedcompensationexpenseTable0": { "order": 1.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other Research and Development Expense.", "label": "OtherResearchAndDevelopmentExpenses", "terseLabel": "Research and development" } } }, "localname": "OtherResearchAndDevelopmentExpenses", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockbasedcompensationexpenseTable0" ], "xbrltype": "monetaryItemType" }, "cmlt_OutstandingHoldersPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding holders, percentage.", "label": "OutstandingHoldersPercentage", "terseLabel": "Outstanding holders, percentage" } } }, "localname": "OutstandingHoldersPercentage", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "cmlt_OutstandingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "outstanding percentage.", "label": "OutstandingPercentage", "terseLabel": "Outstanding percentage" } } }, "localname": "OutstandingPercentage", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "percentItemType" }, "cmlt_PaymentFromSponsor": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "PaymentFromSponsor", "terseLabel": "Payment from sponsor" } } }, "localname": "PaymentFromSponsor", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_PerSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share price.", "label": "PerSharePrice", "terseLabel": "Per share price" } } }, "localname": "PerSharePrice", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "cmlt_PercentageOfHigherMarketValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of higher market value.", "label": "PercentageOfHigherMarketValue", "terseLabel": "Percentage of higher market value" } } }, "localname": "PercentageOfHigherMarketValue", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "cmlt_PercentageOfMarketValues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of market value.", "label": "PercentageOfMarketValues", "terseLabel": "Percentage of market value" } } }, "localname": "PercentageOfMarketValues", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "cmlt_Plan2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Plan2019Member", "terseLabel": "Plan 2019 [Member]" } } }, "localname": "Plan2019Member", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "cmlt_PreclinicalClinicalAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PreclinicalClinicalAssetsMember", "terseLabel": "Preclinical/Clinical Assets [Member]" } } }, "localname": "PreclinicalClinicalAssetsMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/LicenseAgreementsDetails", "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborationsDetails" ], "xbrltype": "domainItemType" }, "cmlt_PreferredStocksSharesAuthorized": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Preferred stock, shares authorized.", "label": "PreferredStocksSharesAuthorized", "terseLabel": "Preferred stock, shares authorized (in Dollars)" } } }, "localname": "PreferredStocksSharesAuthorized", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_PreferredStocksharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock, shares issued.", "label": "PreferredStocksharesIssued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStocksharesIssued", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "cmlt_PrivatePalcementAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "PrivatePalcementAmount", "terseLabel": "Private placement amount" } } }, "localname": "PrivatePalcementAmount", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_PrivatePlacementDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Private Placement (Details) [Line Items]" } } }, "localname": "PrivatePlacementDetailsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/PrivatePlacementDetails" ], "xbrltype": "stringItemType" }, "cmlt_PrivatePlacementDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Private Placement (Details) [Table]" } } }, "localname": "PrivatePlacementDetailsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/PrivatePlacementDetails" ], "xbrltype": "stringItemType" }, "cmlt_PrivatePlacementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Private Placement Disclosure [Abstract]" } } }, "localname": "PrivatePlacementDisclosureAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_PrivatePlacementDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private placement disclosure text Block.", "label": "PrivatePlacementDisclosureTextBlock", "terseLabel": "Private Placement" } } }, "localname": "PrivatePlacementDisclosureTextBlock", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/PrivatePlacement" ], "xbrltype": "textBlockItemType" }, "cmlt_PrivatePlacementsOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "PrivatePlacementsOfWarrants", "terseLabel": "Private placements of warrants", "verboseLabel": "Private warrants outstanding" } } }, "localname": "PrivatePlacementsOfWarrants", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DerivativeWarrantLiabilitiesDetails", "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_ProceedsFormSponsor": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "ProceedsFormSponsor", "terseLabel": "Proceeds form sponsor" } } }, "localname": "ProceedsFormSponsor", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_PropertyAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PropertyAndEquipmentAbstract", "terseLabel": "Property and equipment:" } } }, "localname": "PropertyAndEquipmentAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofpropertyandequipmentnetTable" ], "xbrltype": "stringItemType" }, "cmlt_PropertyAndEquipmentAbstract0": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PropertyAndEquipmentAbstract0", "terseLabel": "Property and equipment:" } } }, "localname": "PropertyAndEquipmentAbstract0", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "stringItemType" }, "cmlt_PropertyandEquipmentNetDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and Equipment, Net (Details) [Line Items]" } } }, "localname": "PropertyandEquipmentNetDetailsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/PropertyandEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "cmlt_PropertyandEquipmentNetDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and Equipment, Net (Details) [Table]" } } }, "localname": "PropertyandEquipmentNetDetailsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/PropertyandEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "cmlt_PropertyandEquipmentNetLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and Equipment, Net [Line Items]" } } }, "localname": "PropertyandEquipmentNetLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/PropertyandEquipmentNet" ], "xbrltype": "stringItemType" }, "cmlt_PropertyandEquipmentNetTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and Equipment, Net [Table]" } } }, "localname": "PropertyandEquipmentNetTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/PropertyandEquipmentNet" ], "xbrltype": "stringItemType" }, "cmlt_PropertyandEquipmentNetTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and Equipment, Net (Tables) [Line Items]" } } }, "localname": "PropertyandEquipmentNetTablesLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/PropertyandEquipmentNetTables" ], "xbrltype": "stringItemType" }, "cmlt_PropertyandEquipmentNetTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and Equipment, Net (Tables) [Table]" } } }, "localname": "PropertyandEquipmentNetTablesTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/PropertyandEquipmentNetTables" ], "xbrltype": "stringItemType" }, "cmlt_ProposedPublicOfferingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Proposed Public Offering [Abstract]" } } }, "localname": "ProposedPublicOfferingAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_ProposedPublicOfferingDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Proposed Public Offering (Details) [Line Items]" } } }, "localname": "ProposedPublicOfferingDetailsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ProposedPublicOfferingDetails" ], "xbrltype": "stringItemType" }, "cmlt_ProposedPublicOfferingDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Proposed Public Offering (Details) [Table]" } } }, "localname": "ProposedPublicOfferingDetailsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ProposedPublicOfferingDetails" ], "xbrltype": "stringItemType" }, "cmlt_ProposedPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ProposedPublicOfferingMember", "terseLabel": "Proposed Public Offering [Member]", "verboseLabel": "Proposed public offering [Member]" } } }, "localname": "ProposedPublicOfferingMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://cmlifesciencesspac.com/role/ProposedPublicOfferingDetails" ], "xbrltype": "domainItemType" }, "cmlt_ProposedPublicOfferingTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ProposedPublicOfferingTextBlock", "terseLabel": "Proposed Public Offering" } } }, "localname": "ProposedPublicOfferingTextBlock", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ProposedPublicOffering" ], "xbrltype": "textBlockItemType" }, "cmlt_PublicPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public per share.", "label": "PublicPerShare", "terseLabel": "Public per Share (in Dollars per share)" } } }, "localname": "PublicPerShare", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "perShareItemType" }, "cmlt_PublicShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PublicShares", "terseLabel": "PublicShares (in Dollars per share)" } } }, "localname": "PublicShares", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "perShareItemType" }, "cmlt_PublicSharesRedeemPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public shares redeem percentage.", "label": "PublicSharesRedeemPercentage", "terseLabel": "Public shares redeem percentage" } } }, "localname": "PublicSharesRedeemPercentage", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "percentItemType" }, "cmlt_PublicWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Public warants", "label": "PublicWarrants", "terseLabel": "Public warrants outstanding" } } }, "localname": "PublicWarrants", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DerivativeWarrantLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_PurchaseAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase Agreement Description.", "label": "PurchaseAgreementDescription", "terseLabel": "Purchase agreement, description" } } }, "localname": "PurchaseAgreementDescription", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "stringItemType" }, "cmlt_PurchaseOfAdditionalShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase of additional shares.", "label": "PurchaseOfAdditionalShares", "terseLabel": "Purchase of additional shares (in Shares)" } } }, "localname": "PurchaseOfAdditionalShares", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "sharesItemType" }, "cmlt_PurchasePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PurchasePrice", "terseLabel": "Purchase price (in Dollars per share)" } } }, "localname": "PurchasePrice", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "perShareItemType" }, "cmlt_RaisingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of raising value.", "label": "RaisingValue", "terseLabel": "Raising value" } } }, "localname": "RaisingValue", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for Recently Issued Accounting Pronouncements.", "label": "RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "cmlt_RecognizedLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "RecognizedLoss", "label": "RecognizedLoss", "terseLabel": "Recognized loss" } } }, "localname": "RecognizedLoss", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_RedemptionOfWarrantsPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RedemptionOfWarrantsPricePerShare", "terseLabel": "Redemption of warrants price per shares (in Dollars per share)" } } }, "localname": "RedemptionOfWarrantsPricePerShare", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "cmlt_RedemptionPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RedemptionPerShare", "terseLabel": "Redemption per share" } } }, "localname": "RedemptionPerShare", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DerivativeWarrantLiabilitiesDetails" ], "xbrltype": "perShareItemType" }, "cmlt_ReductionPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ReductionPerShare", "terseLabel": "Reduction per share (in Dollars per share)" } } }, "localname": "ReductionPerShare", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "perShareItemType" }, "cmlt_RegulatoryMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Regulatory milestone payments.", "label": "RegulatoryMilestonePayments", "terseLabel": "Regulatory milestone payments" } } }, "localname": "RegulatoryMilestonePayments", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/LicenseAgreementsDetails", "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborationsDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_RelatedPartyTransactionsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Line Items]" } } }, "localname": "RelatedPartyTransactionsDetailsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "cmlt_RelatedPartyTransactionsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Table]" } } }, "localname": "RelatedPartyTransactionsDetailsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "cmlt_ResearchAndDevelopmentExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "ResearchAndDevelopmentExpenses", "terseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpenses", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/LicenseAgreementsDetails", "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborationsDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_RestrictedCommonStockDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted common stock, description.", "label": "RestrictedCommonStockDescription", "terseLabel": "Restricted common stock, description" } } }, "localname": "RestrictedCommonStockDescription", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "cmlt_RestrictedStockRepurchaseLiability": { "auth_ref": [], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of restricted stock repurchase liability.", "label": "RestrictedStockRepurchaseLiability", "terseLabel": "Restricted stock repurchase liability" } } }, "localname": "RestrictedStockRepurchaseLiability", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "cmlt_RightOfUseAssetObtainedInExchangeForLeaseObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Right of use asset obtained in exchange for lease obligation.", "label": "RightOfUseAssetObtainedInExchangeForLeaseObligation", "terseLabel": "Right of use asset obtained in exchange for lease obligation" } } }, "localname": "RightOfUseAssetObtainedInExchangeForLeaseObligation", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "cmlt_SaleOfUnitsInInitialPublicOfferingLessFairValueOfDerivativeWarrantLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SaleOfUnitsInInitialPublicOfferingLessFairValueOfDerivativeWarrantLiabilities", "terseLabel": "Sale of units in initial public offering, less fair value of derivative warrant liabilities" } } }, "localname": "SaleOfUnitsInInitialPublicOfferingLessFairValueOfDerivativeWarrantLiabilities", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "cmlt_SaleOfUnitsInInitialPublicOfferingLessFairValueOfDerivativeWarrantLiabilitiesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of units in initial public offering, less fair value of derivative warrant liabilities.", "label": "SaleOfUnitsInInitialPublicOfferingLessFairValueOfDerivativeWarrantLiabilitiesShares", "terseLabel": "Sale of units in initial public offering, less fair value of derivative warrant liabilities (in Shares)" } } }, "localname": "SaleOfUnitsInInitialPublicOfferingLessFairValueOfDerivativeWarrantLiabilitiesShares", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "cmlt_SaleOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of Warrants.", "label": "SaleOfWarrants", "terseLabel": "Sale of warrants (in Shares)" } } }, "localname": "SaleOfWarrants", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "sharesItemType" }, "cmlt_SalesMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sales milestone payments.", "label": "SalesMilestonePayments", "terseLabel": "Sales milestone payments" } } }, "localname": "SalesMilestonePayments", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/LicenseAgreementsDetails", "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborationsDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_ScheduleOfAccruedExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of accrued expenses [Abstract]" } } }, "localname": "ScheduleOfAccruedExpensesAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_ScheduleOfAssetsThatAreMeasuredAtFairValueOnARecurringBasisAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of assets that are measured at fair value on a recurring basis [Abstract]" } } }, "localname": "ScheduleOfAssetsThatAreMeasuredAtFairValueOnARecurringBasisAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_ScheduleOfBasicAndDilutedNetIncomeLossPerCommonShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of basic and diluted net income (loss) per common share [Abstract]" } } }, "localname": "ScheduleOfBasicAndDilutedNetIncomeLossPerCommonShareAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_ScheduleOfComputationOfBasicAndDilutedNetLossPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of computation of basic and diluted net loss per share [Abstract]" } } }, "localname": "ScheduleOfComputationOfBasicAndDilutedNetLossPerShareAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_ScheduleOfComputationOfBasicAndDilutedNetLossPerShareTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of computation of basic and diluted net loss per share table text block.", "label": "ScheduleOfComputationOfBasicAndDilutedNetLossPerShareTableTextBlock", "terseLabel": "Schedule of computation of basic and diluted net loss per share" } } }, "localname": "ScheduleOfComputationOfBasicAndDilutedNetLossPerShareTableTextBlock", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/NetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "cmlt_ScheduleOfCondensedConsolidatedStatementsOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of condensed consolidated statements of cash flows [Abstract]" } } }, "localname": "ScheduleOfCondensedConsolidatedStatementsOfCashFlowsAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_ScheduleOfConsolidatedStatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of consolidated statement of cash flows [Abstract]" } } }, "localname": "ScheduleOfConsolidatedStatementOfCashFlowsAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_ScheduleOfConvertiblePreferredStockOptionsToPurchaseCommonStockAndUnvestedRestrictedStockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of convertible preferred stock, options to purchase common stock and unvested restricted stock [Abstract]" } } }, "localname": "ScheduleOfConvertiblePreferredStockOptionsToPurchaseCommonStockAndUnvestedRestrictedStockAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_ScheduleOfConvertiblePreferredStockOptionsToPurchaseCommonStockAndUnvestedRestrictedStockTableTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of convertible preferred stock, options to purchase common stock and unvested restricted stock table text block.", "label": "ScheduleOfConvertiblePreferredStockOptionsToPurchaseCommonStockAndUnvestedRestrictedStockTableTextblock", "terseLabel": "Schedule of convertible preferred stock, options to purchase common stock and unvested restricted stock" } } }, "localname": "ScheduleOfConvertiblePreferredStockOptionsToPurchaseCommonStockAndUnvestedRestrictedStockTableTextblock", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/NetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "cmlt_ScheduleOfDerivativeWarrantLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of derivative warrant liabilities [Abstract]" } } }, "localname": "ScheduleOfDerivativeWarrantLiabilitiesAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_ScheduleOfFairValueRecurringBasisAndLevelOfInputsUsedInSuchMeasurementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of fair value recurring basis and level of inputs used in such measurements [Abstract]" } } }, "localname": "ScheduleOfFairValueRecurringBasisAndLevelOfInputsUsedInSuchMeasurementsAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_ScheduleOfFutureMinimumLeasePaymentForOperatingLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of future minimum lease payments For operating leases table text block", "label": "ScheduleOfFutureMinimumLeasePaymentForOperatingLeasesTableTextBlock", "terseLabel": "Schedule of total lease payment" } } }, "localname": "ScheduleOfFutureMinimumLeasePaymentForOperatingLeasesTableTextBlock", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentandContingenciesTables0" ], "xbrltype": "textBlockItemType" }, "cmlt_ScheduleOfLeaseCostsInTheCompanySCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of lease costs in the Company\u2019s condensed consolidated statements of operations and comprehensive loss [Abstract]" } } }, "localname": "ScheduleOfLeaseCostsInTheCompanySCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_ScheduleOfNetDeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of net deferred tax assets [Abstract]" } } }, "localname": "ScheduleOfNetDeferredTaxAssetsAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_ScheduleOfNoProvisionForIncomeTaxesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of no provision for income taxes [Abstract]" } } }, "localname": "ScheduleOfNoProvisionForIncomeTaxesAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_ScheduleOfOperationsAndComprehensiveLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of operations and comprehensive loss [Abstract]" } } }, "localname": "ScheduleOfOperationsAndComprehensiveLossAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_ScheduleOfOperationsAndComprehensiveLossTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Operation and Comprehensive Loss Table Text Block.", "label": "ScheduleOfOperationsAndComprehensiveLossTableTextBlock", "terseLabel": "Schedule of operations and comprehensive loss" } } }, "localname": "ScheduleOfOperationsAndComprehensiveLossTableTextBlock", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentandContingenciesTables0" ], "xbrltype": "textBlockItemType" }, "cmlt_ScheduleOfOutstandingConvertiblePreferredStockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of outstanding Convertible Preferred Stock [Abstract]" } } }, "localname": "ScheduleOfOutstandingConvertiblePreferredStockAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_ScheduleOfPropertyAndEquipmentNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of property and equipment, net [Abstract]" } } }, "localname": "ScheduleOfPropertyAndEquipmentNetAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_ScheduleOfPropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of property plant and equipment [Abstract]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_ScheduleOfProvidesQuantitativeInformationRegardingLevel3FairValueMeasurementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of provides quantitative information regarding Level 3 fair value measurements [Abstract]" } } }, "localname": "ScheduleOfProvidesQuantitativeInformationRegardingLevel3FairValueMeasurementsAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_ScheduleOfRestrictedStockActivityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of restricted stock activity [Abstract]" } } }, "localname": "ScheduleOfRestrictedStockActivityAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_ScheduleOfStockBasedCompensationExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of stock-based compensation expense [Abstract]" } } }, "localname": "ScheduleOfStockBasedCompensationExpenseAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_ScheduleOfStockOptionActivityForEmployeeAndNonemployeeAwardsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of stock option activity for employee and nonemployee awards [Abstract]" } } }, "localname": "ScheduleOfStockOptionActivityForEmployeeAndNonemployeeAwardsAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_ScheduleOfTableSummarizeTheCompanySOutstandingConvertiblePreferredStockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of table summarize the Company\u2019s outstanding Convertible Preferred Stock [Abstract]" } } }, "localname": "ScheduleOfTableSummarizeTheCompanySOutstandingConvertiblePreferredStockAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_ScheduleOfTotalLeasePaymentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of total lease payment [Abstract]" } } }, "localname": "ScheduleOfTotalLeasePaymentAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_ScheduleOfWeightedAverageAssumptionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of weighted-average assumption [Abstract]" } } }, "localname": "ScheduleOfWeightedAverageAssumptionAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_ScheduleOfWeightedAverageAssumptionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of weighted-average assumptions [Abstract]" } } }, "localname": "ScheduleOfWeightedAverageAssumptionsAbstract", "nsuri": "http://cmlifesciencesspac.com/20210630", "xbrltype": "stringItemType" }, "cmlt_SeriesACarryingValueinDollars": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SeriesACarryingValueinDollars", "terseLabel": "Carrying Value" } } }, "localname": "SeriesACarryingValueinDollars", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoftablesummarizetheCompanysoutstandingConvertiblePreferredStockTable" ], "xbrltype": "monetaryItemType" }, "cmlt_SeriesAConversionPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SeriesAConversionPrice", "terseLabel": "Conversion Price" } } }, "localname": "SeriesAConversionPrice", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoftablesummarizetheCompanysoutstandingConvertiblePreferredStockTable" ], "xbrltype": "perShareItemType" }, "cmlt_SeriesAConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SeriesAConvertiblePreferredStockMember", "terseLabel": "Series A Convertible Preferred Stock", "verboseLabel": "Series A Convertible Preferred Stock [Member]" } } }, "localname": "SeriesAConvertiblePreferredStockMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoftablesummarizetheCompanysoutstandingConvertiblePreferredStockTable", "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3", "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3_Parentheticals" ], "xbrltype": "domainItemType" }, "cmlt_SeriesALiquidationPreference": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "SeriesALiquidationPreference", "terseLabel": "Liquidation Preference" } } }, "localname": "SeriesALiquidationPreference", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoftablesummarizetheCompanysoutstandingConvertiblePreferredStockTable" ], "xbrltype": "monetaryItemType" }, "cmlt_SeriesAPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SeriesAPurchaseAgreementMember", "terseLabel": "Series A Purchase Agreement [Member]" } } }, "localname": "SeriesAPurchaseAgreementMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "domainItemType" }, "cmlt_SeriesASharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SeriesASharesAuthorized", "terseLabel": "Shares Authorized" } } }, "localname": "SeriesASharesAuthorized", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoftablesummarizetheCompanysoutstandingConvertiblePreferredStockTable" ], "xbrltype": "sharesItemType" }, "cmlt_SeriesASharesIssuedAndOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SeriesASharesIssuedAndOutstanding", "terseLabel": "Shares Issued and Outstanding" } } }, "localname": "SeriesASharesIssuedAndOutstanding", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoftablesummarizetheCompanysoutstandingConvertiblePreferredStockTable" ], "xbrltype": "sharesItemType" }, "cmlt_SeriesBCarryingValueinDollars": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SeriesBCarryingValueinDollars", "terseLabel": "Carrying Value" } } }, "localname": "SeriesBCarryingValueinDollars", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoftablesummarizetheCompanysoutstandingConvertiblePreferredStockTable" ], "xbrltype": "monetaryItemType" }, "cmlt_SeriesBConversionPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SeriesBConversionPrice", "terseLabel": "Conversion Price" } } }, "localname": "SeriesBConversionPrice", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoftablesummarizetheCompanysoutstandingConvertiblePreferredStockTable" ], "xbrltype": "perShareItemType" }, "cmlt_SeriesBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SeriesBConvertiblePreferredStockMember", "terseLabel": "Series B Convertible Preferred Stock", "verboseLabel": "Series B Convertible Preferred Stock [Member]" } } }, "localname": "SeriesBConvertiblePreferredStockMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/NatureofBusinessDetails", "http://cmlifesciencesspac.com/role/ScheduleoftablesummarizetheCompanysoutstandingConvertiblePreferredStockTable", "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3", "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3_Parentheticals" ], "xbrltype": "domainItemType" }, "cmlt_SeriesBLiquidationPreference": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "SeriesBLiquidationPreference", "terseLabel": "Liquidation Preference" } } }, "localname": "SeriesBLiquidationPreference", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoftablesummarizetheCompanysoutstandingConvertiblePreferredStockTable" ], "xbrltype": "monetaryItemType" }, "cmlt_SeriesBPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SeriesBPurchaseAgreementMember", "terseLabel": "Series B Purchase Agreement [Member]" } } }, "localname": "SeriesBPurchaseAgreementMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "cmlt_SeriesBSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SeriesBSharesAuthorized", "terseLabel": "Shares Authorized" } } }, "localname": "SeriesBSharesAuthorized", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoftablesummarizetheCompanysoutstandingConvertiblePreferredStockTable" ], "xbrltype": "sharesItemType" }, "cmlt_SeriesBSharesIssuedAndOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SeriesBSharesIssuedAndOutstanding", "terseLabel": "Shares Issued and Outstanding" } } }, "localname": "SeriesBSharesIssuedAndOutstanding", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoftablesummarizetheCompanysoutstandingConvertiblePreferredStockTable" ], "xbrltype": "sharesItemType" }, "cmlt_ShareAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares Authorized.", "label": "ShareAuthorized", "terseLabel": "Shares Authorized" } } }, "localname": "ShareAuthorized", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofoutstandingConvertiblePreferredStockTable" ], "xbrltype": "sharesItemType" }, "cmlt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm", "terseLabel": "Weighted Average Remaining Contractual Term, Ending balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable0" ], "xbrltype": "durationItemType" }, "cmlt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValueghtedAverageRemainingContractualTermVested": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValueghtedAverageRemainingContractualTermVested", "terseLabel": "Options, Vested", "verboseLabel": "Weighted Average Remaining Contractual Term, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValueghtedAverageRemainingContractualTermVested", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable", "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable0" ], "xbrltype": "sharesItemType" }, "cmlt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRemaingAvailableForGrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRemaingAvailableForGrant", "terseLabel": "No of shares remaining for future grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRemaingAvailableForGrant", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "cmlt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants", "terseLabel": "Options, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable" ], "xbrltype": "sharesItemType" }, "cmlt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstanding", "terseLabel": "Options, Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstanding", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable0" ], "xbrltype": "sharesItemType" }, "cmlt_ShareBasedCompensationArrangementByShareBasedPaymentRestrictedCommonStockFounders": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Founders restricted common stock.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentRestrictedCommonStockFounders", "terseLabel": "Restricted common stock to founders" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentRestrictedCommonStockFounders", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "cmlt_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingByWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingByWeightedAverageExercisePrice", "periodEndLabel": "Weighted-Average Exercise Price, Ending balance (in Dollars per share)", "periodStartLabel": "Weighted-Average Exercise Price, Beginning balance (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingByWeightedAverageExercisePrice", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable0" ], "xbrltype": "perShareItemType" }, "cmlt_ShareBasedCompensationArrangementShareBasedPaymentAwardAggregateIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "ShareBasedCompensationArrangementShareBasedPaymentAwardAggregateIntrinsicValue", "periodEndLabel": "Aggregate Intrinsic Value, Ending balance (in Dollars)", "periodStartLabel": "Aggregate Intrinsic Value, Beginning balance (in Dollars)" } } }, "localname": "ShareBasedCompensationArrangementShareBasedPaymentAwardAggregateIntrinsicValue", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable0" ], "xbrltype": "monetaryItemType" }, "cmlt_ShareBasedCompensationArrangementShareBasedPaymentsAwardOptionsOutstandingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ShareBasedCompensationArrangementShareBasedPaymentsAwardOptionsOutstandingNumber", "periodEndLabel": "Options, Ending balance", "periodStartLabel": "Options, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementShareBasedPaymentsAwardOptionsOutstandingNumber", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable0" ], "xbrltype": "sharesItemType" }, "cmlt_ShareBasedCompensationShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ShareBasedCompensationShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "terseLabel": "Weighted- Average Exercise Price, Outstanding" } } }, "localname": "ShareBasedCompensationShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable" ], "xbrltype": "perShareItemType" }, "cmlt_ShareIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of share of stock issued as of the balance sheet date, including share that had been issued and were previously outstanding but which are now held in the treasury.", "label": "ShareIssued", "terseLabel": "Conversion share issued (in Shares)" } } }, "localname": "ShareIssued", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePromissoryNotesDetails" ], "xbrltype": "sharesItemType" }, "cmlt_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsEffectOfModificationToVestingTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsEffectOfModificationToVestingTerms", "terseLabel": "Number of Shares, Effect of modification to vesting terms" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsEffectOfModificationToVestingTerms", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable0" ], "xbrltype": "sharesItemType" }, "cmlt_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShare", "terseLabel": "Number of Shares, Opening balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShare", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable0" ], "xbrltype": "sharesItemType" }, "cmlt_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageEffectOfModificationToVestingTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageEffectOfModificationToVestingTerms", "terseLabel": "Weighted-Average Grant Date Fair Value, Effect of modification to vesting terms" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageEffectOfModificationToVestingTerms", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable0" ], "xbrltype": "sharesItemType" }, "cmlt_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValues": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValues", "terseLabel": "Weighted-Average Grant Date Fair Value, Opening balance (in Dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValues", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable0" ], "xbrltype": "perShareItemType" }, "cmlt_SharebasedCompensationArrangementSharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "SharebasedCompensationArrangementSharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "terseLabel": "Number of shares options vested (in Dollars)" } } }, "localname": "SharebasedCompensationArrangementSharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_SharebasedCompensationArrangementSharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharebasedCompensationArrangementSharebasedPaymentAwardOptionsNonvestedNumberOfShares", "terseLabel": "Number of Shares, ending balance" } } }, "localname": "SharebasedCompensationArrangementSharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable" ], "xbrltype": "sharesItemType" }, "cmlt_SharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesAuthorized", "terseLabel": "Shares Authorized" } } }, "localname": "SharesAuthorized", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoftablesummarizetheCompanysoutstandingConvertiblePreferredStockTable" ], "xbrltype": "sharesItemType" }, "cmlt_SharesDesignated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares Designated.", "label": "SharesDesignated", "terseLabel": "Preferred stock, shares designated" } } }, "localname": "SharesDesignated", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "sharesItemType" }, "cmlt_SharesIncludedSubjectToForfeitureOverallotmentOption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares included subject to forfeiture over-allotment option.", "label": "SharesIncludedSubjectToForfeitureOverallotmentOption", "terseLabel": "Subject to forfeiture of shares" } } }, "localname": "SharesIncludedSubjectToForfeitureOverallotmentOption", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "cmlt_SharesIssuedAndOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesIssuedAndOutstanding", "terseLabel": "Shares Issued and Outstanding" } } }, "localname": "SharesIssuedAndOutstanding", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoftablesummarizetheCompanysoutstandingConvertiblePreferredStockTable" ], "xbrltype": "sharesItemType" }, "cmlt_SharesIssuedOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "SharesIssuedOutstanding", "terseLabel": "Shares Issued and Outstanding" } } }, "localname": "SharesIssuedOutstanding", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofoutstandingConvertiblePreferredStockTable" ], "xbrltype": "sharesItemType" }, "cmlt_SharesOfRestrictedCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesOfRestrictedCommonStock", "terseLabel": "Shares of restricted common stock" } } }, "localname": "SharesOfRestrictedCommonStock", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "cmlt_SharesRemainFutureGrant": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesRemainFutureGrant", "terseLabel": "Shares remain future grant" } } }, "localname": "SharesRemainFutureGrant", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "cmlt_SharesSubjectToPossibleRedemption": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesSubjectToPossibleRedemption", "terseLabel": "Shares subject to possible redemption" } } }, "localname": "SharesSubjectToPossibleRedemption", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "cmlt_SharesUnderlyingAwardsForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesUnderlyingAwardsForfeited", "terseLabel": "Shares underlying awards forfeited" } } }, "localname": "SharesUnderlyingAwardsForfeited", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "cmlt_SponsorAndDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SponsorAndDirectorMember", "terseLabel": "Sponsor and Director [Member]" } } }, "localname": "SponsorAndDirectorMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/PrivatePlacementDetails" ], "xbrltype": "domainItemType" }, "cmlt_SponsorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SponsorMember", "terseLabel": "Sponsor [Member]" } } }, "localname": "SponsorMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/PrivatePlacementDetails", "http://cmlifesciencesspac.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "cmlt_StateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "StateMember", "terseLabel": "State [Member]" } } }, "localname": "StateMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "cmlt_StockBasedCompensationDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) [Line Items]" } } }, "localname": "StockBasedCompensationDetailsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "cmlt_StockBasedCompensationDetailsScheduleofrestrictedstockactivityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) - Schedule of restricted stock activity [Line Items]" } } }, "localname": "StockBasedCompensationDetailsScheduleofrestrictedstockactivityLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable", "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable0" ], "xbrltype": "stringItemType" }, "cmlt_StockBasedCompensationDetailsScheduleofrestrictedstockactivityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) - Schedule of restricted stock activity [Table]" } } }, "localname": "StockBasedCompensationDetailsScheduleofrestrictedstockactivityTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable", "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable0" ], "xbrltype": "stringItemType" }, "cmlt_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) - Schedule of stock-based compensation expense [Line Items]" } } }, "localname": "StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockbasedcompensationexpenseTable", "http://cmlifesciencesspac.com/role/ScheduleofstockbasedcompensationexpenseTable0" ], "xbrltype": "stringItemType" }, "cmlt_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) - Schedule of stock-based compensation expense [Table]" } } }, "localname": "StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockbasedcompensationexpenseTable", "http://cmlifesciencesspac.com/role/ScheduleofstockbasedcompensationexpenseTable0" ], "xbrltype": "stringItemType" }, "cmlt_StockBasedCompensationDetailsScheduleofstockoptionactivityforemployeeandnonemployeeawardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) - Schedule of stock option activity for employee and nonemployee awards [Line Items]" } } }, "localname": "StockBasedCompensationDetailsScheduleofstockoptionactivityforemployeeandnonemployeeawardsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable", "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable0" ], "xbrltype": "stringItemType" }, "cmlt_StockBasedCompensationDetailsScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) - Schedule of stock option activity for employee and nonemployee awards [Table]" } } }, "localname": "StockBasedCompensationDetailsScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable", "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable0" ], "xbrltype": "stringItemType" }, "cmlt_StockBasedCompensationDetailsScheduleofweightedaverageassumptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) - Schedule of weighted-average assumption [Line Items]" } } }, "localname": "StockBasedCompensationDetailsScheduleofweightedaverageassumptionLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofweightedaverageassumptionTable" ], "xbrltype": "stringItemType" }, "cmlt_StockBasedCompensationDetailsScheduleofweightedaverageassumptionTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) - Schedule of weighted-average assumption [Table]" } } }, "localname": "StockBasedCompensationDetailsScheduleofweightedaverageassumptionTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofweightedaverageassumptionTable" ], "xbrltype": "stringItemType" }, "cmlt_StockBasedCompensationDetailsScheduleofweightedaverageassumptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) - Schedule of weighted-average assumptions [Line Items]" } } }, "localname": "StockBasedCompensationDetailsScheduleofweightedaverageassumptionsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofweightedaverageassumptionsTable" ], "xbrltype": "stringItemType" }, "cmlt_StockBasedCompensationDetailsScheduleofweightedaverageassumptionsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) - Schedule of weighted-average assumptions [Table]" } } }, "localname": "StockBasedCompensationDetailsScheduleofweightedaverageassumptionsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofweightedaverageassumptionsTable" ], "xbrltype": "stringItemType" }, "cmlt_StockBasedCompensationDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) [Table]" } } }, "localname": "StockBasedCompensationDetailsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "cmlt_StockBasedCompensationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation [Line Items]" } } }, "localname": "StockBasedCompensationLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensation" ], "xbrltype": "stringItemType" }, "cmlt_StockBasedCompensationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation [Table]" } } }, "localname": "StockBasedCompensationTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensation" ], "xbrltype": "stringItemType" }, "cmlt_StockBasedCompensationTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Tables) [Line Items]" } } }, "localname": "StockBasedCompensationTablesLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "cmlt_StockBasedCompensationTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Tables) [Table]" } } }, "localname": "StockBasedCompensationTablesTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "cmlt_StockIssuedDuringPeriodSharesModificationOfRestrictedCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Modification of restricted common stock.", "label": "StockIssuedDuringPeriodSharesModificationOfRestrictedCommonStock", "terseLabel": "Modification of restricted common stock (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesModificationOfRestrictedCommonStock", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "cmlt_StockIssuedDuringPeriodValueIssuanceOfSeriesBConvertiblePreferredStockNetOfIssuanceCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of issuance of Series B convertible preferred stock, net of issuance costs.", "label": "StockIssuedDuringPeriodValueIssuanceOfSeriesBConvertiblePreferredStockNetOfIssuanceCosts", "terseLabel": "Issuance of Series B convertible preferred stock, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueIssuanceOfSeriesBConvertiblePreferredStockNetOfIssuanceCosts", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "cmlt_StockIssuedDuringPeriodValueModificationOfRestrictedCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of modification of restricted common stock.", "label": "StockIssuedDuringPeriodValueModificationOfRestrictedCommonStock", "terseLabel": "Modification of restricted common stock" } } }, "localname": "StockIssuedDuringPeriodValueModificationOfRestrictedCommonStock", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "cmlt_StockOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding stock options", "label": "StockOptions", "terseLabel": "Outstanding stock options" } } }, "localname": "StockOptions", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofconvertiblepreferredstockoptionstopurchasecommonstockandunvestedrestrictedstockTable", "http://cmlifesciencesspac.com/role/ScheduleofconvertiblepreferredstockoptionstopurchasecommonstockandunvestedrestrictedstockTable0" ], "xbrltype": "sharesItemType" }, "cmlt_StockOptionsGrantedTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock options granted term.", "label": "StockOptionsGrantedTerm", "terseLabel": "Stock options granted term" } } }, "localname": "StockOptionsGrantedTerm", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "cmlt_StockbasedCompensationDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock-based compensation, description.", "label": "StockbasedCompensationDescription", "terseLabel": "Stock-based compensation, description" } } }, "localname": "StockbasedCompensationDescription", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "cmlt_StockbasedCompensationExpenseDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock-based compensation expense, description.", "label": "StockbasedCompensationExpenseDescription", "terseLabel": "Stock-based compensation expense, description" } } }, "localname": "StockbasedCompensationExpenseDescription", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "cmlt_StockholdersEquityDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity (Details) [Line Items]" } } }, "localname": "StockholdersEquityDetailsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "cmlt_StockholdersEquityDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity (Details) [Table]" } } }, "localname": "StockholdersEquityDetailsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "cmlt_StockholdersEquityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity [Line Items]" } } }, "localname": "StockholdersEquityLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockholdersEquity" ], "xbrltype": "stringItemType" }, "cmlt_StockholdersEquityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity [Table]" } } }, "localname": "StockholdersEquityTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockholdersEquity" ], "xbrltype": "stringItemType" }, "cmlt_SubsequentEventsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Line Items]" } } }, "localname": "SubsequentEventsDetailsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "cmlt_SubsequentEventsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Table]" } } }, "localname": "SubsequentEventsDetailsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "cmlt_SubsequentEventsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Line Items]" } } }, "localname": "SubsequentEventsLineItems", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/SubsequentEvents" ], "xbrltype": "stringItemType" }, "cmlt_SubsequentEventsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Table]" } } }, "localname": "SubsequentEventsTable", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/SubsequentEvents" ], "xbrltype": "stringItemType" }, "cmlt_SugemalimabEQ176Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SugemalimabEQ176Member", "terseLabel": "Sugemalimab /EQ176 [Member]" } } }, "localname": "SugemalimabEQ176Member", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/LicenseAgreementsDetails", "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborationsDetails" ], "xbrltype": "domainItemType" }, "cmlt_TargetFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Target fee.", "label": "TargetFee", "terseLabel": "Target fee" } } }, "localname": "TargetFee", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborationsDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_TotalAccruedExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "TotalAccruedExpenses", "terseLabel": "Total accrued expenses" } } }, "localname": "TotalAccruedExpenses", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofaccruedexpensesTable", "http://cmlifesciencesspac.com/role/ScheduleofaccruedexpensesTable0" ], "xbrltype": "monetaryItemType" }, "cmlt_TotalOutstandingBalance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "TotalOutstandingBalance", "terseLabel": "Total outstanding balance" } } }, "localname": "TotalOutstandingBalance", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_TotalPotentialDevelopmentAndRegulatoryPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total potential development and regulatory payments.", "label": "TotalPotentialDevelopmentAndRegulatoryPayments", "terseLabel": "Total potential development and regulatory payments" } } }, "localname": "TotalPotentialDevelopmentAndRegulatoryPayments", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/LicenseAgreementsDetails", "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborationsDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_TotalPotentialSalesMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total potential sales milestone payments.", "label": "TotalPotentialSalesMilestonePayments", "terseLabel": "Total potential sales milestone payments" } } }, "localname": "TotalPotentialSalesMilestonePayments", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/LicenseAgreementsDetails", "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborationsDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_TransferOfPublicWarrantsToLevel1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "TransferOfPublicWarrantsToLevel1", "label": "TransferOfPublicWarrantsToLevel1", "terseLabel": "Transfer of Public Warrants to Level 1" } } }, "localname": "TransferOfPublicWarrantsToLevel1", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofderivativewarrantliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "cmlt_TwentyNinteenPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TwentyNinteenPlanMember", "terseLabel": "2019 Plan [Member]" } } }, "localname": "TwentyNinteenPlanMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "cmlt_UltimateSettlementPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ultimate settlement percentage.", "label": "UltimateSettlementPercentage", "terseLabel": "Ultimate settlement percentage" } } }, "localname": "UltimateSettlementPercentage", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "cmlt_UnderwritersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UnderwritersMember", "terseLabel": "Underwriters [Member]" } } }, "localname": "UnderwritersMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/PrivatePlacementDetails" ], "xbrltype": "domainItemType" }, "cmlt_UnrecognizedCompensationExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unrecognized compensation expense.", "label": "UnrecognizedCompensationExpense", "terseLabel": "Unrecognized compensation expense (in Dollars)" } } }, "localname": "UnrecognizedCompensationExpense", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_UnvestedRestrictedStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unvested restricted stock.", "label": "UnvestedRestrictedStock", "terseLabel": "Unvested restricted stock" } } }, "localname": "UnvestedRestrictedStock", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofconvertiblepreferredstockoptionstopurchasecommonstockandunvestedrestrictedstockTable", "http://cmlifesciencesspac.com/role/ScheduleofconvertiblepreferredstockoptionstopurchasecommonstockandunvestedrestrictedstockTable0" ], "xbrltype": "sharesItemType" }, "cmlt_VotingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Voting percentage.", "label": "VotingPercentage", "terseLabel": "Voting percentage" } } }, "localname": "VotingPercentage", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "percentItemType" }, "cmlt_WarrantLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrant Liability means Borrower's liability in connection with warrants to purchase equity securities issued by Borrower, determined in accordance with GAAP.", "label": "WarrantLiabilities", "periodEndLabel": "Level 3 Warrant liabilities at June 30, 2021", "periodStartLabel": "Level 3 Warrant liabilities at March 31, 2021" } } }, "localname": "WarrantLiabilities", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofderivativewarrantliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "cmlt_WarrantLiabilityPrivatePlacementWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "WarrantLiabilityPrivatePlacementWarrants", "label": "WarrantLiabilityPrivatePlacementWarrants", "terseLabel": "Private Placement Warrants" } } }, "localname": "WarrantLiabilityPrivatePlacementWarrants", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "monetaryItemType" }, "cmlt_WarrantLiabilityPublicWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "WarrantLiabilityPublicWarrants", "label": "WarrantLiabilityPublicWarrants", "terseLabel": "Public Warrants" } } }, "localname": "WarrantLiabilityPublicWarrants", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "monetaryItemType" }, "cmlt_WarrantsDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WarrantsDescription", "terseLabel": "Warrants, description" } } }, "localname": "WarrantsDescription", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DerivativeWarrantLiabilitiesDetails", "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "cmlt_WarrantsIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WarrantsIssued", "terseLabel": "Warrants issued" } } }, "localname": "WarrantsIssued", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DerivativeWarrantLiabilitiesDetails" ], "xbrltype": "sharesItemType" }, "cmlt_WarrantsSold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants sold.", "label": "WarrantsSold", "terseLabel": "Warrants sold (in Shares)" } } }, "localname": "WarrantsSold", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "cmlt_WarrantsTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WarrantsTerm", "terseLabel": "Warrants term" } } }, "localname": "WarrantsTerm", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DerivativeWarrantLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "cmlt_WeightedAverageCommonSharesOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WeightedAverageCommonSharesOutstandingBasicAndDiluted", "terseLabel": "Weighted average common shares outstanding, basic and diluted" } } }, "localname": "WeightedAverageCommonSharesOutstandingBasicAndDiluted", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofcomputationofbasicanddilutednetlosspershareTable", "http://cmlifesciencesspac.com/role/ScheduleofcomputationofbasicanddilutednetlosspershareTable0" ], "xbrltype": "sharesItemType" }, "cmlt_WeightedAverageExercisePriceVested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted- Average Exercise Price, Vested.\r \n.", "label": "WeightedAverageExercisePriceVested", "terseLabel": "Weighted- Average Exercise Price, Vested" } } }, "localname": "WeightedAverageExercisePriceVested", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable" ], "xbrltype": "perShareItemType" }, "cmlt_WorkInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WorkInProgressMember", "terseLabel": "Work In Progress [Member]" } } }, "localname": "WorkInProgressMember", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "cmlt_WorkingCapitalDeficiency": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "WorkingCapitalDeficiency", "terseLabel": "Working capital deficiency" } } }, "localname": "WorkingCapitalDeficiency", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "cmlt_WorkingCapitalLoans": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Working Capital Loans.", "label": "WorkingCapitalLoans", "terseLabel": "Working capital loans (in Dollars)" } } }, "localname": "WorkingCapitalLoans", "nsuri": "http://cmlifesciencesspac.com/20210630", "presentation": [ "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description", "terseLabel": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cmlifesciencesspac.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cmlifesciencesspac.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cmlifesciencesspac.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cmlifesciencesspac.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cmlifesciencesspac.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cmlifesciencesspac.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cmlifesciencesspac.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r600" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cmlifesciencesspac.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cmlifesciencesspac.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cmlifesciencesspac.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cmlifesciencesspac.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cmlifesciencesspac.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "srt_CondensedCashFlowStatementTable": { "auth_ref": [ "r111", "r386", "r595" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations.", "label": "Condensed Cash Flow Statement [Table]" } } }, "localname": "CondensedCashFlowStatementTable", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofconsolidatedstatementofcashflowsTable" ], "xbrltype": "stringItemType" }, "srt_CondensedCashFlowStatementsCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Condensed Cash Flow Statements, Captions [Line Items]" } } }, "localname": "CondensedCashFlowStatementsCaptionsLineItems", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofconsolidatedstatementofcashflowsTable" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r111", "r219", "r224", "r230", "r388", "r389", "r394", "r395", "r456", "r572", "r585", "r596", "r597", "r598" ], "lang": { "en-us": { "role": { "documentation": "Information by consolidated entity or group of entities.", "label": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy", "http://cmlifesciencesspac.com/role/AccruedExpenses", "http://cmlifesciencesspac.com/role/AccruedExpensesTables", "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies", "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails", "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables", "http://cmlifesciencesspac.com/role/CashCashEquivalentsandRestrictedCash", "http://cmlifesciencesspac.com/role/CashCashEquivalentsandRestrictedCashTables", "http://cmlifesciencesspac.com/role/CommitmentandContingenciesTables", "http://cmlifesciencesspac.com/role/CommitmentandContingenciesTables0", "http://cmlifesciencesspac.com/role/CommitmentsandContingencies", "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails", "http://cmlifesciencesspac.com/role/CommonStock", "http://cmlifesciencesspac.com/role/CommonStockDetails", "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet", "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow", "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement", "http://cmlifesciencesspac.com/role/ConvertiblePreferredStock", "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails", "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockTables", "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockTables0", "http://cmlifesciencesspac.com/role/ConvertiblePromissoryNotes", "http://cmlifesciencesspac.com/role/ConvertiblePromissoryNotesDetails", "http://cmlifesciencesspac.com/role/EmployeeBenefits", "http://cmlifesciencesspac.com/role/EmployeeBenefitsDetails", "http://cmlifesciencesspac.com/role/FairValueMeasurements", "http://cmlifesciencesspac.com/role/FairValueMeasurementsTables", "http://cmlifesciencesspac.com/role/IncomeTaxes", "http://cmlifesciencesspac.com/role/IncomeTaxesDetails", "http://cmlifesciencesspac.com/role/IncomeTaxesTables", "http://cmlifesciencesspac.com/role/LicenseAgreements", "http://cmlifesciencesspac.com/role/LicenseAgreementsDetails", "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborations", "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborationsDetails", "http://cmlifesciencesspac.com/role/NatureofBusiness", "http://cmlifesciencesspac.com/role/NatureofBusinessDetails", "http://cmlifesciencesspac.com/role/NetLossPerShare", "http://cmlifesciencesspac.com/role/NetLossPerShareTables", "http://cmlifesciencesspac.com/role/PropertyandEquipmentNet", "http://cmlifesciencesspac.com/role/PropertyandEquipmentNetDetails", "http://cmlifesciencesspac.com/role/PropertyandEquipmentNetTables", "http://cmlifesciencesspac.com/role/ScheduleofaccruedexpensesTable", "http://cmlifesciencesspac.com/role/ScheduleofaccruedexpensesTable0", "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable0", "http://cmlifesciencesspac.com/role/ScheduleofcomputationofbasicanddilutednetlosspershareTable", "http://cmlifesciencesspac.com/role/ScheduleofcomputationofbasicanddilutednetlosspershareTable0", "http://cmlifesciencesspac.com/role/ScheduleofcondensedconsolidatedstatementsofcashflowsTable", "http://cmlifesciencesspac.com/role/ScheduleofconsolidatedstatementofcashflowsTable", "http://cmlifesciencesspac.com/role/ScheduleofconvertiblepreferredstockoptionstopurchasecommonstockandunvestedrestrictedstockTable", "http://cmlifesciencesspac.com/role/ScheduleofconvertiblepreferredstockoptionstopurchasecommonstockandunvestedrestrictedstockTable0", "http://cmlifesciencesspac.com/role/ScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsTable", "http://cmlifesciencesspac.com/role/ScheduleofleasecostsintheCompanyscondensedconsolidatedstatementsofoperationsandcomprehensivelossTable", "http://cmlifesciencesspac.com/role/ScheduleofnetdeferredtaxassetsTable", "http://cmlifesciencesspac.com/role/ScheduleofnoprovisionforincometaxesTable", "http://cmlifesciencesspac.com/role/ScheduleofoutstandingConvertiblePreferredStockTable", "http://cmlifesciencesspac.com/role/ScheduleofpropertyandequipmentnetTable", "http://cmlifesciencesspac.com/role/ScheduleofpropertyplantandequipmentTable", "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable", "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable0", "http://cmlifesciencesspac.com/role/ScheduleofstockbasedcompensationexpenseTable", "http://cmlifesciencesspac.com/role/ScheduleofstockbasedcompensationexpenseTable0", "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable", "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable0", "http://cmlifesciencesspac.com/role/ScheduleoftablesummarizetheCompanysoutstandingConvertiblePreferredStockTable", "http://cmlifesciencesspac.com/role/ScheduleofweightedaverageassumptionTable", "http://cmlifesciencesspac.com/role/ScheduleofweightedaverageassumptionsTable", "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3", "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3_Parentheticals", "http://cmlifesciencesspac.com/role/StockBasedCompensation", "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails", "http://cmlifesciencesspac.com/role/StockBasedCompensationTables", "http://cmlifesciencesspac.com/role/StockholdersEquity", "http://cmlifesciencesspac.com/role/StockholdersEquityDetails", "http://cmlifesciencesspac.com/role/SubsequentEvents", "http://cmlifesciencesspac.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r111", "r219", "r224", "r230", "r388", "r389", "r394", "r395", "r456", "r572", "r585", "r596", "r597", "r598" ], "lang": { "en-us": { "role": { "documentation": "Entity or group of entities consolidated into reporting entity.", "label": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy", "http://cmlifesciencesspac.com/role/AccruedExpenses", "http://cmlifesciencesspac.com/role/AccruedExpensesTables", "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies", "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails", "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables", "http://cmlifesciencesspac.com/role/CommitmentsandContingencies", "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails", "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet", "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow", "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement", "http://cmlifesciencesspac.com/role/EmployeeBenefits", "http://cmlifesciencesspac.com/role/FairValueMeasurements", "http://cmlifesciencesspac.com/role/FairValueMeasurementsTables", "http://cmlifesciencesspac.com/role/ScheduleoftablesummarizetheCompanysoutstandingConvertiblePreferredStockTable", "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3", "http://cmlifesciencesspac.com/role/StockholdersEquity", "http://cmlifesciencesspac.com/role/StockholdersEquityDetails", "http://cmlifesciencesspac.com/role/SubsequentEvents", "http://cmlifesciencesspac.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r235", "r279", "r314", "r316", "r469", "r470", "r471", "r472", "r473", "r474", "r493", "r545", "r547", "r573", "r574" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails", "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails", "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://cmlifesciencesspac.com/role/ScheduleofpropertyandequipmentnetTable", "http://cmlifesciencesspac.com/role/ScheduleofprovidesquantitativeinformationregardingLevel3fairvaluemeasurementsTable", "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r235", "r279", "r314", "r316", "r469", "r470", "r471", "r472", "r473", "r474", "r493", "r545", "r547", "r573", "r574" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails", "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails", "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://cmlifesciencesspac.com/role/ScheduleofpropertyandequipmentnetTable", "http://cmlifesciencesspac.com/role/ScheduleofprovidesquantitativeinformationregardingLevel3fairvaluemeasurementsTable", "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r235", "r279", "r302", "r314", "r316", "r469", "r470", "r471", "r472", "r473", "r474", "r493", "r545", "r547", "r573", "r574" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails", "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails", "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://cmlifesciencesspac.com/role/ScheduleofpropertyandequipmentnetTable", "http://cmlifesciencesspac.com/role/ScheduleofprovidesquantitativeinformationregardingLevel3fairvaluemeasurementsTable", "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r235", "r279", "r302", "r314", "r316", "r469", "r470", "r471", "r472", "r473", "r474", "r493", "r545", "r547", "r573", "r574" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails", "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails", "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://cmlifesciencesspac.com/role/ScheduleofpropertyandequipmentnetTable", "http://cmlifesciencesspac.com/role/ScheduleofprovidesquantitativeinformationregardingLevel3fairvaluemeasurementsTable", "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfCondensedCashFlowStatementTableTextBlock": { "auth_ref": [ "r599" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations.", "label": "Condensed Cash Flow Statement [Table Text Block]", "terseLabel": "Schedule of consolidated statement of cash flows" } } }, "localname": "ScheduleOfCondensedCashFlowStatementTableTextBlock", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r167", "r168", "r299", "r300", "r546", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r584", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594" ], "lang": { "en-us": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r167", "r168", "r299", "r300", "r546", "r555", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r584", "r586" ], "lang": { "en-us": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r169", "r452" ], "lang": { "en-us": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesAndLoansReceivableNetCurrent": { "auth_ref": [ "r4", "r25", "r51", "r170", "r171", "r530" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.", "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Convertible note" } } }, "localname": "AccountsNotesAndLoansReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofnetdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "ACCRUED EXPENSES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/AccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r40", "r459" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRentCurrentAndNoncurrent": { "auth_ref": [ "r16", "r18", "r513", "r533" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements.", "label": "Accrued Rent", "terseLabel": "Annual rent" } } }, "localname": "AccruedRentCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r26", "r350", "r459" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r113", "r114", "r115", "r347", "r348", "r349", "r408" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital", "verboseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "verboseLabel": "Reconciliation of net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r318", "r344", "r352" ], "calculation": { "http://cmlifesciencesspac.com/role/ScheduleofstockbasedcompensationexpenseTable0": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense, Total", "totalLabel": "Total stock-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockbasedcompensationexpenseTable", "http://cmlifesciencesspac.com/role/ScheduleofstockbasedcompensationexpenseTable0" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r75", "r93", "r255", "r431" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization expense" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r107", "r153", "r161", "r165", "r186", "r219", "r220", "r221", "r223", "r224", "r225", "r226", "r227", "r228", "r230", "r231", "r388", "r394", "r421", "r457", "r459", "r510", "r532" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r8", "r54", "r107", "r186", "r219", "r220", "r221", "r223", "r224", "r225", "r226", "r227", "r228", "r230", "r231", "r388", "r394", "r421", "r457", "r459" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties.", "label": "Assets, Fair Value Adjustment", "terseLabel": "Increased fair value" } } }, "localname": "AssetsFairValueAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsHeldInTrust": { "auth_ref": [ "r102" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.", "label": "Assets Held-in-trust", "terseLabel": "Investments held in Trust Account" } } }, "localname": "AssetsHeldInTrust", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsHeldInTrustCurrent": { "auth_ref": [ "r102" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate within one year of the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.", "label": "Assets Held-in-trust, Current", "terseLabel": "U.S. Treasury securities" } } }, "localname": "AssetsHeldInTrustCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r178" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gain" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r179" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "terseLabel": "Gross Unrealized Loss" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r176", "r195" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "terseLabel": "Amortized Costs" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r174", "r177", "r195", "r516" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Aggregate FairValue" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r320", "r346" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails", "http://cmlifesciencesspac.com/role/ScheduleofleasecostsintheCompanyscondensedconsolidatedstatementsofoperationsandcomprehensivelossTable", "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable", "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable0", "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r313", "r315" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails", "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://cmlifesciencesspac.com/role/ProposedPublicOfferingDetails", "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r313", "r315", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails", "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://cmlifesciencesspac.com/role/ProposedPublicOfferingDetails", "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.", "label": "Business Acquisition, Description of Acquired Entity", "terseLabel": "Proposed public offering description" } } }, "localname": "BusinessAcquisitionDescriptionOfAcquiredEntity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ProposedPublicOfferingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Percentage of ownership interest" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "terseLabel": "Initial Business Combination price (in Dollars per share)" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessCombinationControlObtainedDescription": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "This element represents a description of how the entity obtained control of the acquired entity.", "label": "Business Combination, Control Obtained Description", "terseLabel": "Business combination, desccription" } } }, "localname": "BusinessCombinationControlObtainedDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/DerivativeWarrantLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationReasonForBusinessCombination": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "This element represents a description of the primary reason for the business combination which may consist of general categories such as top-line growth, synergistic benefits, market share, and diversification and the more detailed factors that might apply.", "label": "Business Combination, Reason for Business Combination", "terseLabel": "Description of underwriting agreement" } } }, "localname": "BusinessCombinationReasonForBusinessCombination", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferred policy acquisition costs, including the nature, type, and amount of capitalized costs incurred to write or acquire insurance contracts, and the basis for and methodologies applied in capitalizing and amortizing such costs.", "label": "Deferred Policy Acquisition Costs, Policy [Policy Text Block]", "terseLabel": "Deferred Policy Acquisition Costs, Policy [Policy Text Block]" } } }, "localname": "CapitalizationOfDeferredPolicyAcquisitionCostsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r33", "r459", "r553", "r554" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://cmlifesciencesspac.com/role/NatureofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r33", "r95" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://cmlifesciencesspac.com/role/ScheduleofcondensedconsolidatedstatementsofcashflowsTable": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://cmlifesciencesspac.com/role/ScheduleofconsolidatedstatementofcashflowsTable": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash \u2013 end of the period", "periodStartLabel": "Cash \u2013 beginning of the period", "terseLabel": "Cash", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet", "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow", "http://cmlifesciencesspac.com/role/ScheduleofcondensedconsolidatedstatementsofcashflowsTable", "http://cmlifesciencesspac.com/role/ScheduleofconsolidatedstatementofcashflowsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsTable" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.", "label": "Cash and Cash Equivalents Disclosure [Text Block]", "terseLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH" } } }, "localname": "CashAndCashEquivalentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CashCashEquivalentsandRestrictedCash" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Net change in cash" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r11", "r96" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r11", "r96", "r508" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r89", "r95", "r100" ], "calculation": { "http://cmlifesciencesspac.com/role/ScheduleofcondensedconsolidatedstatementsofcashflowsTable": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://cmlifesciencesspac.com/role/ScheduleofconsolidatedstatementofcashflowsTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and restricted cash, end of period", "periodStartLabel": "Cash and restricted cash, beginning of period", "totalLabel": "Total cash and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow", "http://cmlifesciencesspac.com/role/ScheduleofcondensedconsolidatedstatementsofcashflowsTable", "http://cmlifesciencesspac.com/role/ScheduleofconsolidatedstatementofcashflowsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r33" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Carrying Value" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofoutstandingConvertiblePreferredStockTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of non-cash financing activities" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r104", "r107", "r127", "r128", "r129", "r132", "r134", "r140", "r141", "r142", "r186", "r219", "r224", "r225", "r226", "r230", "r231", "r276", "r277", "r281", "r285", "r421", "r577" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet", "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement", "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails", "http://cmlifesciencesspac.com/role/ConvertiblePromissoryNotesDetails", "http://cmlifesciencesspac.com/role/DerivativeWarrantLiabilitiesDetails", "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://cmlifesciencesspac.com/role/NatureofBusinessDetails", "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails", "http://cmlifesciencesspac.com/role/ScheduleofoutstandingConvertiblePreferredStockTable", "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3", "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Price per warrant (in Dollars per share)", "verboseLabel": "Issued price (in Dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/PrivatePlacementDetails", "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Purchase aggregate warrants" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/PrivatePlacementDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper [Member]", "verboseLabel": "Commercial Paper (Due within 90 Days) [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable0", "http://cmlifesciencesspac.com/role/ScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsTable" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r48", "r215", "r518", "r538" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r211", "r212", "r214", "r216", "r559" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "netLabel": "Class A Common Stock [Member]", "terseLabel": "Class A Common Stock", "verboseLabel": "Class A" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement", "http://cmlifesciencesspac.com/role/DerivativeWarrantLiabilitiesDetails", "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://cmlifesciencesspac.com/role/ScheduleofbasicanddilutednetincomelosspercommonshareTable", "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3", "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Common Class B [Member]", "netLabel": "Class B Common Stock [Member]", "terseLabel": "Class B Common Stock", "verboseLabel": "Class B" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement", "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails", "http://cmlifesciencesspac.com/role/ScheduleofbasicanddilutednetincomelosspercommonshareTable", "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3", "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r113", "r114", "r408" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockOtherSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.", "label": "Common Stock, Other Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockOtherSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommonStockDetails", "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails", "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommonStockDetails", "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "verboseLabel": "Common stock, shares, issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommonStockDetails", "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r24", "r293" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r24", "r459" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Class A common stock, $0.0001 par value; 380,000,000 shares authorized; 8,478,548 shares issued and outstanding (excluding 46,721,452 shares subject to possible redemption)" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockVotingRights": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Common Stock, Voting Rights", "terseLabel": "Voting rights, description" } } }, "localname": "CommonStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommonUnitIssuanceValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stated value of common units of ownership issued by a limited liability company (LLC).", "label": "Common Unit, Issuance Value", "terseLabel": "Rise up, value (in Dollars)" } } }, "localname": "CommonUnitIssuanceValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment [Member]", "verboseLabel": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofpropertyandequipmentnetTable", "http://cmlifesciencesspac.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r146", "r526" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of Credit Risk and Significant Suppliers" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r101", "r390" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Work-in-progress [Member]" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofpropertyandequipmentnetTable" ], "xbrltype": "domainItemType" }, "us-gaap_ConversionOfStockDescription": { "auth_ref": [ "r97", "r98", "r99" ], "lang": { "en-us": { "role": { "documentation": "A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Description", "terseLabel": "Conversion of stock ,description" } } }, "localname": "ConversionOfStockDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Conversion of Stock [Line Items]" } } }, "localname": "ConversionOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofoutstandingConvertiblePreferredStockTable", "http://cmlifesciencesspac.com/role/ScheduleoftablesummarizetheCompanysoutstandingConvertiblePreferredStockTable" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r97", "r98", "r99" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Issued", "terseLabel": "Sale of stock" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails", "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ConversionOfStockTable": { "auth_ref": [ "r97", "r98", "r99" ], "lang": { "en-us": { "role": { "documentation": "This table may be used to disclose all the information related to converting stock into another financial instrument(s) in a noncash (or part noncash) transaction. It may include a description sufficient information to understand the nature and purpose of the conversion, as well as the financial instruments converted from and to (for example, preferred, common, treasury, etc.) the amounts converted, the new shares issued, and the value of the new shares issued, if applicable. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock [Table]" } } }, "localname": "ConversionOfStockTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofoutstandingConvertiblePreferredStockTable", "http://cmlifesciencesspac.com/role/ScheduleoftablesummarizetheCompanysoutstandingConvertiblePreferredStockTable" ], "xbrltype": "stringItemType" }, "us-gaap_ConvertibleNotesPayableCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible Notes Payable, Current", "terseLabel": "Convertible promissory notes" } } }, "localname": "ConvertibleNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r22", "r23", "r288", "r294", "r295" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "terseLabel": "Convertible preferred shares" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofconvertiblepreferredstockoptionstopurchasecommonstockandunvestedrestrictedstockTable0" ], "xbrltype": "sharesItemType" }, "us-gaap_CostOfGoodsAndServicesSoldDepreciation": { "auth_ref": [ "r76", "r205" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for allocation of cost of tangible asset over its useful life directly used in production of good and rendering of service.", "label": "Cost, Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "CostOfGoodsAndServicesSoldDepreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/PropertyandEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r103", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r249", "r256", "r257", "r259", "r266" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "CONVERTIBLE PROMISSORY NOTES" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePromissoryNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r15", "r16", "r17", "r106", "r111", "r232", "r233", "r234", "r235", "r236", "r237", "r239", "r245", "r246", "r247", "r248", "r250", "r251", "r252", "r253", "r254", "r255", "r262", "r263", "r264", "r265", "r432", "r511", "r514", "r528" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoftablesummarizetheCompanysoutstandingConvertiblePreferredStockTable" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r234", "r260" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Conversion Price (per share)", "verboseLabel": "Conversion price (in Dollars per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePromissoryNotesDetails", "http://cmlifesciencesspac.com/role/ScheduleofoutstandingConvertiblePreferredStockTable" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Per share excess of preference in liquidation over convertible debt instrument's if-converted par or stated value of share.", "label": "Debt Instrument, Convertible, Liquidation Preference, Per Share", "terseLabel": "Conversion price per share (in Dollars per share)" } } }, "localname": "DebtInstrumentConvertibleLiquidationPreferencePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePromissoryNotesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.", "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "terseLabel": "Conversion price percentage" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePromissoryNotesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r232", "r262", "r263", "r430", "r432", "r433" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Loan amount (in Dollars)", "verboseLabel": "Aggregate purchase note" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePromissoryNotesDetails", "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r46", "r261", "r430", "r432" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Ownership interest percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r47", "r106", "r111", "r232", "r233", "r234", "r235", "r236", "r237", "r239", "r245", "r246", "r247", "r248", "r250", "r251", "r252", "r253", "r254", "r255", "r262", "r263", "r264", "r265", "r432" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoftablesummarizetheCompanysoutstandingConvertiblePreferredStockTable" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredCosts": { "auth_ref": [ "r14", "r509", "r531" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.", "label": "Deferred Costs, Noncurrent", "terseLabel": "Deferred offering costs associated with initial public offering" } } }, "localname": "DeferredCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCurrentAndNoncurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of deferred costs.", "label": "Deferred Costs", "terseLabel": "Deferred Costs" } } }, "localname": "DeferredCostsCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/InitialPublicOfferingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeNoncurrent": { "auth_ref": [ "r217" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred Income, Noncurrent", "terseLabel": "Deferred underwriting commissions" } } }, "localname": "DeferredIncomeNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r19", "r20", "r364", "r512", "r527" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedLabel": "Total deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofnetdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "terseLabel": "Intangible assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofnetdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r365" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "terseLabel": "Total gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofnetdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "auth_ref": [ "r370", "r371" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.", "label": "Deferred Tax Assets, in Process Research and Development", "terseLabel": "Research and development tax credits" } } }, "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofnetdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r367" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "terseLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofnetdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r370", "r371" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating losses" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofnetdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r370", "r371" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofnetdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r370", "r371" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities", "terseLabel": "Accrued bonus" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofnetdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r366" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofnetdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r358", "r367" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "terseLabel": "Net deferred tax asset (liability)" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofnetdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Gross [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofnetdeferredtaxassetsTable" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r312" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Company contribution" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/EmployeeBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r93", "r205" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationExpenseOnReclassifiedAssets": { "auth_ref": [ "r203", "r204" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For the asset that is reclassified back to held and use from held-for-sale, the depreciation expense recognized when the asset is reclassified. This represents the difference between the carrying value at the time the decision to reclassify is made and the carrying amount that the asset would have had if it had never been classified as held for sale (including consideration of depreciation expense).", "label": "Depreciation Expense on Reclassified Assets", "terseLabel": "Depreciation expense" } } }, "localname": "DepreciationExpenseOnReclassifiedAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/PropertyandEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r404" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Offering costs associated with derivative warrant liabilities" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r407", "r410" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivative Warrant Liabilities" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/DerivativeWarrantLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r401", "r403", "r405" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofprovidesquantitativeinformationregardingLevel3fairvaluemeasurementsTable" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r57", "r58", "r59", "r420" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Derivative warrant liabilities at January 25, 2021 (inception)" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofderivativewarrantliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "auth_ref": [ "r57" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Noncurrent", "terseLabel": "Derivative warrant liabilities" } } }, "localname": "DerivativeLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r110", "r399", "r400", "r401", "r402", "r406" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivative\u00a0Warrant Liabilities" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r40", "r109", "r222", "r224", "r225", "r229", "r230", "r231", "r451" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Outstanding Balance (in Dollars)" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r109", "r222", "r224", "r225", "r229", "r230", "r231", "r451", "r517", "r539" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to Related Parties", "terseLabel": "Amount borrowed (in Dollars)" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Basic and diluted net income/loss per share (in Dollars per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r135", "r136" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r135", "r136", "r137", "r138" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "NET LOSS PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/NetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofnoprovisionforincometaxesTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r108", "r359", "r376" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Profit before tax at federal statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofnoprovisionforincometaxesTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r359", "r376" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofnoprovisionforincometaxesTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r359", "r376" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State tax benefit, net of federal effects" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofnoprovisionforincometaxesTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r359", "r376" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "terseLabel": "Research and development credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofnoprovisionforincometaxesTable" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for employee benefit and equity-based compensation.", "label": "Employee Benefits and Share-based Compensation", "terseLabel": "Accrued compensation" } } }, "localname": "EmployeeBenefitsAndShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofaccruedexpensesTable", "http://cmlifesciencesspac.com/role/ScheduleofaccruedexpensesTable0" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Recognize remaining weighted-average period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock Option Plan [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable0" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r66", "r67", "r68", "r113", "r114", "r115", "r117", "r122", "r124", "r139", "r187", "r293", "r296", "r347", "r348", "r349", "r373", "r374", "r408", "r422", "r423", "r424", "r425", "r426", "r428", "r548", "r549", "r550", "r601" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/DerivativeWarrantLiabilitiesDetails", "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails", "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentsPolicy": { "auth_ref": [ "r34", "r88", "r185", "r421" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.", "label": "Equity Method Investments [Policy Text Block]", "terseLabel": "Investments Held in Trust Account" } } }, "localname": "EquityMethodInvestmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ExcessStockSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.", "label": "Excess Stock, Shares Issued", "terseLabel": "Common stock, shares issued", "verboseLabel": "Excluding shares" } } }, "localname": "ExcessStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails", "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r93", "r267" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement": { "order": 7.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Change in fair value of derivative warrant liabilities", "terseLabel": "Change in the fair value of derivative warrant liabilites" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow", "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable", "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable0" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable", "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable0" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Schedule of assets that are measured at fair value on a recurring basis" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r411", "r412" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of fair value recurring basis and level of inputs used in such measurements" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails", "http://cmlifesciencesspac.com/role/LicenseAgreementsDetails", "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r411", "r417" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails", "http://cmlifesciencesspac.com/role/LicenseAgreementsDetails", "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r247", "r262", "r263", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r311", "r412", "r466", "r467", "r468" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable", "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable0", "http://cmlifesciencesspac.com/role/ScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsTable", "http://cmlifesciencesspac.com/role/ScheduleofprovidesquantitativeinformationregardingLevel3fairvaluemeasurementsTable" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r247", "r303", "r304", "r309", "r311", "r412", "r466" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable", "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable0", "http://cmlifesciencesspac.com/role/ScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r247", "r262", "r263", "r303", "r304", "r309", "r311", "r412", "r467" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable", "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable0", "http://cmlifesciencesspac.com/role/ScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r247", "r262", "r263", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r311", "r412", "r468" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable", "http://cmlifesciencesspac.com/role/ScheduleofprovidesquantitativeinformationregardingLevel3fairvaluemeasurementsTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r247", "r262", "r263", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r311", "r466", "r467", "r468" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable0", "http://cmlifesciencesspac.com/role/ScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r418", "r419" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value Option" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_FederalDepositInsuranceCorporationPremiumExpense": { "auth_ref": [ "r523" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for Federal Deposit Insurance Corporation (FDIC) insurance.", "label": "Federal Deposit Insurance Corporation Premium Expense", "terseLabel": "Federal Deposit Insurance" } } }, "localname": "FederalDepositInsuranceCorporationPremiumExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r436", "r444" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Total future minimum lease obligations (lease liability)" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoftotalleasepaymentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r444" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "terseLabel": "Total lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoftotalleasepaymentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r444" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoftotalleasepaymentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r444" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "2021" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoftotalleasepaymentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r444" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Five", "terseLabel": "2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoftotalleasepaymentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r444" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoftotalleasepaymentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r444" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoftotalleasepaymentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r444" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Two", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoftotalleasepaymentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r441", "r445" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Recognize over remaining weighted-average" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r180", "r181", "r182", "r183", "r184", "r189", "r190", "r191", "r192", "r194", "r196", "r197", "r198", "r199", "r258", "r291", "r407", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r577", "r578", "r579", "r580", "r581", "r582", "r583" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable0" ], "xbrltype": "stringItemType" }, "us-gaap_FranchisorCosts": { "auth_ref": [], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate costs incurred that are directly related to activities, including but not limited to, generating franchise revenues from franchisor owned outlets and franchised outlets.", "label": "Franchisor Costs", "terseLabel": "Franchise tax payable" } } }, "localname": "FranchisorCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures [Member]", "verboseLabel": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofpropertyandequipmentnetTable", "http://cmlifesciencesspac.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "auth_ref": [ "r403" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement": { "order": 6.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "terseLabel": "Change in fair value of convertible promissory notes" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnInvestments": { "auth_ref": [ "r79", "r93", "r175" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) on investment.", "label": "Gain (Loss) on Investments", "negatedLabel": "Income from investments held in Trust Account" } } }, "localname": "GainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfDerivatives": { "auth_ref": [ "r93", "r522" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.", "label": "Gain (Loss) on Sale of Derivatives", "terseLabel": "Loss upon issuance of private placement warrants" } } }, "localname": "GainLossOnSaleOfDerivatives", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r77" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative costs" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofleasecostsintheCompanyscondensedconsolidatedstatementsofoperationsandcomprehensivelossTable", "http://cmlifesciencesspac.com/role/ScheduleofoperationsandcomprehensivelossTable", "http://cmlifesciencesspac.com/role/ScheduleofstockbasedcompensationexpenseTable" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofprovidesquantitativeinformationregardingLevel3fairvaluemeasurementsTable" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "netLabel": "Initial Public Offering [Member]", "terseLabel": "Proposed Public Offering [Member]", "verboseLabel": "Public Offering [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails", "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://cmlifesciencesspac.com/role/InitialPublicOfferingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InProcessResearchAndDevelopmentPolicy": { "auth_ref": [ "r38", "r355" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.", "label": "In Process Research and Development, Policy [Policy Text Block]", "terseLabel": "Research and Development Funding" } } }, "localname": "InProcessResearchAndDevelopmentPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r107", "r116", "r153", "r160", "r163", "r164", "r166", "r186", "r219", "r220", "r221", "r224", "r225", "r226", "r227", "r228", "r230", "r231", "r387", "r409", "r421" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Less: Company\u2019s portion available to be withdrawn to pay taxes" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofbasicanddilutednetincomelosspercommonshareTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r208", "r210" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofoperationsandcomprehensivelossTable", "http://cmlifesciencesspac.com/role/ScheduleofstockbasedcompensationexpenseTable" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofoperationsandcomprehensivelossTable", "http://cmlifesciencesspac.com/role/ScheduleofstockbasedcompensationexpenseTable" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r108", "r360", "r362", "r369", "r375", "r377", "r378", "r379", "r380" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r65", "r356", "r357", "r362", "r363", "r368", "r372" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r359" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "federal NOL carryforwards" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": { "auth_ref": [ "r359" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount", "terseLabel": "Research and development tax" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r359" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "terseLabel": "State NOL carryforwards" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r92" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r92" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Non-cash lease expense" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r92" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r92" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r92" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest Income, Other", "terseLabel": "Interest income" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r443", "r445" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "terseLabel": "Total lease costs" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofleasecostsintheCompanyscondensedconsolidatedstatementsofoperationsandcomprehensivelossTable", "http://cmlifesciencesspac.com/role/ScheduleofoperationsandcomprehensivelossTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.", "label": "Lease Expiration Date", "terseLabel": "Expire date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "dateItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r206" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements [Member]", "verboseLabel": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofpropertyandequipmentnetTable", "http://cmlifesciencesspac.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Lease Agreements" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Lease term" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LessorOperatingLeaseDescription": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Description of lessor's operating lease.", "label": "Lessor, Operating Lease, Description", "terseLabel": "Lease agreement, description" } } }, "localname": "LessorOperatingLeaseDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r43", "r107", "r162", "r186", "r219", "r220", "r221", "r224", "r225", "r226", "r227", "r228", "r230", "r231", "r389", "r394", "r395", "r421", "r457", "r458" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r30", "r107", "r186", "r421", "r459", "r515", "r536" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r45", "r107", "r186", "r219", "r220", "r221", "r224", "r225", "r226", "r227", "r228", "r230", "r231", "r389", "r394", "r395", "r421", "r457", "r458", "r459" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Non-current liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.", "label": "Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate", "terseLabel": "Bear interest rate" } } }, "localname": "LongTermDebtPercentageBearingFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable0", "http://cmlifesciencesspac.com/role/ScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsTable" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r143", "r152" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "NATURE OF BUSINESS" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/NatureofBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r89" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows from Financing Activities:", "verboseLabel": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r89" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows from Investing Activities", "verboseLabel": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r89", "r91", "r94" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows from Operating Activities:", "verboseLabel": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r61", "r63", "r68", "r72", "r94", "r107", "r116", "r118", "r119", "r120", "r121", "r123", "r124", "r130", "r153", "r160", "r163", "r164", "r166", "r186", "r219", "r220", "r221", "r224", "r225", "r226", "r227", "r228", "r230", "r231", "r409", "r421", "r520", "r540" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow", "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement", "http://cmlifesciencesspac.com/role/ScheduleofcomputationofbasicanddilutednetlosspershareTable0" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r118", "r119", "r120", "r121", "r125", "r126", "r131", "r134", "r153", "r160", "r163", "r164", "r166" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net income attributable", "totalLabel": "Net loss and comprehensive loss" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement", "http://cmlifesciencesspac.com/role/ScheduleofbasicanddilutednetincomelosspercommonshareTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": { "auth_ref": [ "r271", "r392", "r393" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.", "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest", "terseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofbasicanddilutednetincomelosspercommonshareTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentInLease": { "auth_ref": [ "r172", "r188", "r191", "r446" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of net investment in sales-type and direct financing leases.", "label": "Net Investment in Lease, before Allowance for Credit Loss", "terseLabel": "Lease allowance" } } }, "localname": "NetInvestmentInLease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoninterestIncomeOtherOperatingIncome": { "auth_ref": [ "r70", "r519", "r542" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue earned, classified as other, excluding interest income.", "label": "Noninterest Income, Other Operating Income", "terseLabel": "Other income" } } }, "localname": "NoninterestIncomeOtherOperatingIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r80" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expenses)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableNet": { "auth_ref": [ "r25", "r170", "r193" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.", "label": "Financing Receivable, after Allowance for Credit Loss", "terseLabel": "Improvement allowance" } } }, "localname": "NotesReceivableNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r153", "r160", "r163", "r164", "r166" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r439", "r445" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease costs" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofleasecostsintheCompanyscondensedconsolidatedstatementsofoperationsandcomprehensivelossTable", "http://cmlifesciencesspac.com/role/ScheduleofoperationsandcomprehensivelossTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r436" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofnetdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r436" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Lease liability, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r436" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Lease liability, non-current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r435" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r442", "r445" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r441", "r445" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r2", "r398" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Description of Organization and Business Operations" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r52", "r459" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Prepaid and other current assets", "verboseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails", "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r39" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r62", "r64", "r66", "r67", "r69", "r73", "r293", "r422", "r427", "r428", "r521", "r541" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Net loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofcomputationofbasicanddilutednetlosspershareTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenses": { "auth_ref": [ "r78", "r543" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense classified as other.", "label": "Other Expenses", "terseLabel": "Other expenses" } } }, "localname": "OtherExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherGeneralAndAdministrativeExpense": { "auth_ref": [ "r77" ], "calculation": { "http://cmlifesciencesspac.com/role/ScheduleofstockbasedcompensationexpenseTable0": { "order": 2.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general and administrative expense classified as other.", "label": "Other General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "OtherGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockbasedcompensationexpenseTable0" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "netLabel": "Other income (expense):", "terseLabel": "Other income (expenses):", "verboseLabel": "Other income:" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNoncashExpense": { "auth_ref": [ "r94" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.", "label": "Other Noncash Expense", "terseLabel": "Offering costs associated with derivative warrant liabilities" } } }, "localname": "OtherNoncashExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherResearchAndDevelopmentExpense": { "auth_ref": [ "r354" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other research and development expense.", "label": "Other Research and Development Expense", "terseLabel": "Research and development amount" } } }, "localname": "OtherResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherRestrictedAssetsNoncurrent": { "auth_ref": [ "r556", "r558" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets that are pledged or subject to withdrawal restrictions, classified as other.", "label": "Other Restricted Assets, Noncurrent", "terseLabel": "Prepaid and other current assets" } } }, "localname": "OtherRestrictedAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Over-Allotment Option [Member]" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails", "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://cmlifesciencesspac.com/role/InitialPublicOfferingDetails", "http://cmlifesciencesspac.com/role/PrivatePlacementDetails", "http://cmlifesciencesspac.com/role/ProposedPublicOfferingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForLeasingCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for costs that are essential to originate the lease and would not otherwise have been incurred without the lease agreement. Amount includes, but is not limited to, cash outflows to evaluate the lessee's credit condition, guarantees, and collateral and cash outflows for costs incurred in negotiating, processing, and executing the lease agreement.", "label": "Payments for Leasing Costs", "terseLabel": "Cash payments" } } }, "localname": "PaymentsForLeasingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRent": { "auth_ref": [ "r90" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments to lessor's for use of assets under operating leases.", "label": "Payments for Rent", "terseLabel": "Initial annual rent" } } }, "localname": "PaymentsForRent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfInitialPublicOffering": { "auth_ref": [ "r85" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.", "label": "Payments for Repurchase of Initial Public Offering", "terseLabel": "Deferred underwriting commissions in connection with the initial public offering" } } }, "localname": "PaymentsForRepurchaseOfInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r86" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "negatedLabel": "Offering costs paid" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAssetsInvestingActivities": { "auth_ref": [ "r82" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate cash payments for a combination of transactions that are classified as investing activities in which assets, which may include securities, other types of investments, or productive assets, are purchased from third-party sellers. This element can be used by entities to aggregate payments for all asset purchases that are classified as investing activities.", "label": "Payments to Acquire Assets, Investing Activities", "negatedLabel": "Cash deposited in Trust Account" } } }, "localname": "PaymentsToAcquireAssetsInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r81" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r320", "r346" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockConvertibleConversionPrice": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Per share conversion price of preferred stock.", "label": "Preferred Stock, Convertible, Conversion Price", "terseLabel": "Conversion price (in Dollars per share)" } } }, "localname": "PreferredStockConvertibleConversionPrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails", "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r23", "r276" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in Dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails", "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "verboseLabel": "Preferred stock, designated shares" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r23", "r276" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r23", "r459" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock value" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r6", "r31", "r32" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r5", "r7", "r200", "r201" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "netLabel": "Private Placement Warrants [Member]", "terseLabel": "Private Placement [Member]", "verboseLabel": "Proposed Public Offering [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails", "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://cmlifesciencesspac.com/role/FairValueMeasurementsDetails", "http://cmlifesciencesspac.com/role/PrivatePlacementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r84" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from issuance of convertible promissory notes" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r83" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Proceeds received from initial public offering, gross" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r83" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock", "verboseLabel": "Proceeds of business combination" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow", "http://cmlifesciencesspac.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r83" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds from Issuance of Convertible Preferred Stock", "terseLabel": "Proceeds from issuance of convertible preferred stock, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r83" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds from Issuance of Preferred Stock and Preference Stock", "terseLabel": "Gross proceeds (in Dollars)" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r83" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Proceeds received from private placement", "verboseLabel": "Gross Proceeds (in Dollars)" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow", "http://cmlifesciencesspac.com/role/PrivatePlacementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r83" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from Issuance of Warrants", "terseLabel": "Issuance of Public and Private Warrants" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofderivativewarrantliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r84" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from Related Party Debt", "terseLabel": "Proceeds from note payable to related party" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfDebt": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.", "label": "Proceeds from (Repayments of) Debt", "terseLabel": "Net proceeds of additional purchase" } } }, "localname": "ProceedsFromRepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "auth_ref": [], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.", "label": "Proceeds from (Repayments of) Related Party Debt", "terseLabel": "Repayment of note payable to related party" } } }, "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r83" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds from Stock Plans", "terseLabel": "Aggregate proceeds" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/NatureofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductionTaxExpense": { "auth_ref": [ "r71" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A tax assessed on oil and gas production.", "label": "Production Tax Expense", "terseLabel": "Franchise tax expenses" } } }, "localname": "ProductionTaxExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r61", "r63", "r68", "r87", "r107", "r116", "r123", "r124", "r153", "r160", "r163", "r164", "r166", "r186", "r219", "r220", "r221", "r224", "r225", "r226", "r227", "r228", "r230", "r231", "r387", "r391", "r393", "r396", "r397", "r409", "r421", "r524" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r37", "r207" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofpropertyandequipmentnetTable", "http://cmlifesciencesspac.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r209", "r560", "r561", "r562" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "PROPERTY AND EQUIPMENT, NET" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/PropertyandEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Property, Plant and Equipment, Estimated Useful Lives", "terseLabel": "Estimated Useful Life" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofpropertyandequipmentnetTable" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r36", "r206" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofpropertyandequipmentnetTable", "http://cmlifesciencesspac.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofpropertyandequipmentnetTable", "http://cmlifesciencesspac.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment [Member]", "terseLabel": "Property, Plant and Equipment [Member]" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r12", "r13", "r207", "r459", "r525", "r537" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "verboseLabel": "Property and equipment, net:" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet", "http://cmlifesciencesspac.com/role/ScheduleofpropertyandequipmentnetTable", "http://cmlifesciencesspac.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentOther": { "auth_ref": [ "r207" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Other, Gross", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of depreciation (related to long-lived, depreciable flight assets owned by the entity and used in the entity's principle business operations and capitalized assets classified as property, plant and equipment that are owned by the entity) that has been recognized in the income statement.", "label": "Property, Plant, and Equipment, Owned, Accumulated Depreciation", "negatedLabel": "Less: Accumulated depreciation" } } }, "localname": "PropertyPlantAndEquipmentOwnedAccumulatedDepreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofpropertyandequipmentnetTable", "http://cmlifesciencesspac.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r35", "r207", "r560", "r561" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r12", "r207" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment, net", "verboseLabel": "Schedule of property plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/PropertyandEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r12", "r206" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofpropertyandequipmentnetTable", "http://cmlifesciencesspac.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated Useful Life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofpropertyandequipmentnetTable" ], "xbrltype": "durationItemType" }, "us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount": { "auth_ref": [ "r269", "r270", "r272", "r273" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "As of the reporting date, the carrying amount of noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. The noncontrolling interest holder's ownership (or holders' ownership) may be in the form of preferred shares (regardless of class), preferred partnership units (regardless of class), preferential membership interests, or any other form of preferred equity regardless of investee entity legal form.", "label": "Redeemable Noncontrolling Interest, Equity, Preferred, Carrying Amount", "terseLabel": "Convertible preferred stock value" } } }, "localname": "RedeemableNoncontrollingInterestEquityPreferredCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r310", "r450", "r451" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/LicenseAgreementsDetails", "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborationsDetails", "http://cmlifesciencesspac.com/role/PrivatePlacementDetails", "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails", "http://cmlifesciencesspac.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r450", "r453" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction, Amounts of Transaction", "terseLabel": "Additional Amount (in Dollars)" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r310", "r450", "r451", "r453" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r310", "r450", "r453", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/LicenseAgreementsDetails", "http://cmlifesciencesspac.com/role/LicenseAgreementsandDiscoveryCollaborationsDetails", "http://cmlifesciencesspac.com/role/PrivatePlacementDetails", "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails", "http://cmlifesciencesspac.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r448", "r449", "r451", "r454", "r455" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r354", "r494", "r575" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofleasecostsintheCompanyscondensedconsolidatedstatementsofoperationsandcomprehensivelossTable", "http://cmlifesciencesspac.com/role/ScheduleofoperationsandcomprehensivelossTable", "http://cmlifesciencesspac.com/role/ScheduleofstockbasedcompensationexpenseTable" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r100", "r508", "r534" ], "calculation": { "http://cmlifesciencesspac.com/role/ScheduleofcondensedconsolidatedstatementsofcashflowsTable": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://cmlifesciencesspac.com/role/ScheduleofconsolidatedstatementofcashflowsTable": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofcondensedconsolidatedstatementsofcashflowsTable", "http://cmlifesciencesspac.com/role/ScheduleofconsolidatedstatementofcashflowsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r11", "r95", "r100", "r508", "r534" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Cash" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/NatureofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsTable" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r9", "r14", "r100", "r557" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock Activity [Member]", "verboseLabel": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable", "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r27", "r296", "r350", "r459", "r535", "r551", "r552" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAppropriated": { "auth_ref": [ "r55", "r105", "r274", "r275", "r529" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "A segregation of retained earnings which is unavailable for dividend distribution. Includes also retained earnings appropriated for loss contingencies.", "label": "Retained Earnings, Appropriated", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAppropriated", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/NatureofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r113", "r114", "r115", "r117", "r122", "r124", "r187", "r347", "r348", "r349", "r373", "r374", "r408", "r548", "r550" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Net of issuance costs" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3_Parentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails", "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails", "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://cmlifesciencesspac.com/role/InitialPublicOfferingDetails", "http://cmlifesciencesspac.com/role/PrivatePlacementDetails", "http://cmlifesciencesspac.com/role/ProposedPublicOfferingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "netLabel": "Sale of stock in shares", "terseLabel": "Sale of stock in shares (in Shares)", "verboseLabel": "Number of common stock issued" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://cmlifesciencesspac.com/role/InitialPublicOfferingDetails", "http://cmlifesciencesspac.com/role/ProposedPublicOfferingDetails", "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Stock price (in Dollars per share)", "netLabel": "Price per share (in Dollars per share)", "terseLabel": "Sale value per unit (in Dollars per share)", "totalLabel": "Price per share", "verboseLabel": "Sale price per share (in Dollars per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails", "http://cmlifesciencesspac.com/role/DerivativeWarrantLiabilitiesDetails", "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://cmlifesciencesspac.com/role/InitialPublicOfferingDetails", "http://cmlifesciencesspac.com/role/ProposedPublicOfferingDetails", "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails", "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/AccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "terseLabel": "Schedule of condensed consolidated statements of cash flows" } } }, "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CashCashEquivalentsandRestrictedCashTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.", "label": "Schedule of Changes in Fair Value of Plan Assets [Table Text Block]", "terseLabel": "Schedule of derivative warrant liabilities" } } }, "localname": "ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Schedule of stock-based compensation expense" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfConversionsOfStockTextBlock": { "auth_ref": [ "r97", "r98", "r99" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to converting stock into another financial instrument(s) in a noncash (or part noncash) transaction.", "label": "Schedule of Conversions of Stock [Table Text Block]", "terseLabel": "Schedule of outstanding Convertible Preferred Stock", "verboseLabel": "Schedule of table summarize the Company\u2019s outstanding Convertible Preferred Stock" } } }, "localname": "ScheduleOfConversionsOfStockTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockTables", "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockTables0" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of net deferred tax assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of basic and diluted net income (loss) per common share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of no provision for income taxes" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Schedule of lease costs in the Company\u2019s condensed consolidated statements of operations and comprehensive loss" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r37", "r207" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofpropertyandequipmentnetTable", "http://cmlifesciencesspac.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of restricted stock activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r323", "r331", "r333" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of stock option activity for employee and nonemployee awards" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "netLabel": "Schedule of weighted-average assumptions", "terseLabel": "Schedule of provides quantitative information regarding Level 3 fair value measurements", "verboseLabel": "Schedule of weighted-average assumption" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/FairValueMeasurementsTables", "http://cmlifesciencesspac.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuritiesBorrowedGross": { "auth_ref": [ "r56", "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before effects of master netting arrangements, of securities borrowed from entities in exchange for collateral. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Securities Borrowed, Gross", "terseLabel": "Borrowing amount" } } }, "localname": "SecuritiesBorrowedGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r53" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security Deposit", "terseLabel": "Security deposit" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r154", "r155", "r156", "r157", "r158", "r159", "r167" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]", "netLabel": "Series A Preferred Stock [Member]", "terseLabel": "Series A Convertible Preferred Stock", "verboseLabel": "Series A [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet", "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails", "http://cmlifesciencesspac.com/role/ConvertiblePromissoryNotesDetails", "http://cmlifesciencesspac.com/role/ScheduleofoutstandingConvertiblePreferredStockTable", "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series B Preferred Stock [Member]", "netLabel": "Series B Preferred Stock [Member]", "terseLabel": "Series B Convertible Preferred Stock", "verboseLabel": "Series B [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet", "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails", "http://cmlifesciencesspac.com/role/ScheduleofoutstandingConvertiblePreferredStockTable", "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.", "label": "Business Combination [Member]", "netLabel": "Business Acquisition [Member]", "terseLabel": "Business Acquisition [member]", "verboseLabel": "Business Combinations [Member]" } } }, "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails", "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r92" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Options, Forfeited/cancelled", "negatedTerseLabel": "Options, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable", "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable0" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share", "terseLabel": "Number of stock options granted (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Weighted Average Remaining Contractual Term (years), Outstanding", "verboseLabel": "Weighted Average Remaining Contractual Term, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable", "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable0" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "terseLabel": "Options, Vested", "verboseLabel": "Restricted stock issued vesting" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable0", "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average intrinsic value of award vested under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Intrinsic Value, Amount Per Share", "terseLabel": "Weighted-Average Exercise Price, Vested and expected to vest (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable0" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price", "terseLabel": "Exercise price (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofprovidesquantitativeinformationregardingLevel3fairvaluemeasurementsTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofprovidesquantitativeinformationregardingLevel3fairvaluemeasurementsTable", "http://cmlifesciencesspac.com/role/ScheduleofweightedaverageassumptionTable", "http://cmlifesciencesspac.com/role/ScheduleofweightedaverageassumptionsTable" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofprovidesquantitativeinformationregardingLevel3fairvaluemeasurementsTable", "http://cmlifesciencesspac.com/role/ScheduleofweightedaverageassumptionTable", "http://cmlifesciencesspac.com/role/ScheduleofweightedaverageassumptionsTable" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free rate", "verboseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofprovidesquantitativeinformationregardingLevel3fairvaluemeasurementsTable", "http://cmlifesciencesspac.com/role/ScheduleofweightedaverageassumptionTable", "http://cmlifesciencesspac.com/role/ScheduleofweightedaverageassumptionsTable" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "The highest quantity of shares an employee can purchase under the plan per period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee", "terseLabel": "Restricted common stock issued" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Issued stock options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted- Average Exercise Price, Forfeited/cancelled", "verboseLabel": "Weighted-Average Exercise Price, Forfeited (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable", "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable0" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Number of Shares, Granted", "verboseLabel": "Options, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable", "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable0", "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable0" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted- Average Grant Date Fair Value, Granted", "verboseLabel": "Weighted-Average Grant Date Fair Value, Granted (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable", "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable0" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r325", "r346" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Options, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted- Average Exercise Price, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Options, Vested and expected" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r333" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest (in Dollars)", "verboseLabel": "Fair value of restricted stock grant (in Dollars)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable0", "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Options, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted- Average Exercise Price, Vested and expected", "verboseLabel": "Weighted-Average Exercise Price, Vested (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable", "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable0" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period", "terseLabel": "Restricted common stock to a strategic partner" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r317", "r321" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails", "http://cmlifesciencesspac.com/role/ScheduleofleasecostsintheCompanyscondensedconsolidatedstatementsofoperationsandcomprehensivelossTable", "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted- Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted- Average Exercise Price, Granted", "verboseLabel": "Weighted-Average Exercise Price, Granted (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable", "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable0" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r320", "r322" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Unit price (in Dollars per share)", "verboseLabel": "Purchase price (in Dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofprovidesquantitativeinformationregardingLevel3fairvaluemeasurementsTable", "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested", "terseLabel": "Aggregate Intrinsic Value, Vested (in Dollars)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable0" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r338", "r351" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Term (years)", "verboseLabel": "Expected term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofprovidesquantitativeinformationregardingLevel3fairvaluemeasurementsTable", "http://cmlifesciencesspac.com/role/ScheduleofweightedaverageassumptionTable", "http://cmlifesciencesspac.com/role/ScheduleofweightedaverageassumptionsTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares", "terseLabel": "Number of Shares, opening balance", "verboseLabel": "Number of Shares, Opening balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable", "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable0" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options forfeited.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares", "negatedLabel": "Number of Shares, Forfeited" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable", "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable0" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options forfeited.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted- Average Grant Date Fair Value, Forfeited", "verboseLabel": "Weighted-Average Grant Date Fair Value, Forfeited (in Dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable", "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable0" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "periodEndLabel": "Weighted- Average Grant Date Fair Value, ending balance", "periodStartLabel": "Weighted- Average Grant Date Fair Value, opening balance", "terseLabel": "Weighted-Average Grant Date Fair Value, Opening balance (in Dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable", "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable0" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term (years), Vested", "verboseLabel": "Weighted Average Remaining Contractual Term, Vested and expected to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable", "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable0" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term (years), Outstanding", "verboseLabel": "Weighted Average Remaining Contractual Term (years), Vested and expected" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares", "negatedLabel": "Number of Shares, Vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable", "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable0" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted- Average Grant Date Fair Value, Vested", "verboseLabel": "Weighted-Average Grant Date Fair Value, Vested (in Dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable", "http://cmlifesciencesspac.com/role/ScheduleofrestrictedstockactivityTable0" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares sold", "netLabel": "Issuance shares", "terseLabel": "Shares transferred", "verboseLabel": "Issuance of shares (in Shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommonStockDetails", "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails", "http://cmlifesciencesspac.com/role/NatureofBusinessDetails", "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "netLabel": "Price per share (in Dollars per share)", "terseLabel": "Share price per share (in Dollars per share)", "verboseLabel": "Price per warrant (in Dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails", "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognition of changes in redemption value of mandatorily redeemable shares. Provides the period over which changes in redemption value are accreted, usually from the issuance date (or from the date that it becomes probable that the security will become redeemable, if later) to the earliest redemption date of the security.", "label": "Shares Subject to Mandatory Redemption, Changes in Redemption Value, Policy [Policy Text Block]", "terseLabel": "Classification and Accretion of Convertible Preferred Stock" } } }, "localname": "SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsTable" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoffairvaluerecurringbasisandlevelofinputsusedinsuchmeasurementsTable" ], "xbrltype": "domainItemType" }, "us-gaap_SoftwareDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Internally developed software for sale, licensing or long-term internal use.", "label": "Software Development [Member]", "terseLabel": "Capitalized website development [Member]" } } }, "localname": "SoftwareDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofpropertyandequipmentnetTable" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r22", "r23", "r24", "r104", "r107", "r127", "r128", "r129", "r132", "r134", "r140", "r141", "r142", "r186", "r219", "r224", "r225", "r226", "r230", "r231", "r276", "r277", "r281", "r285", "r293", "r421", "r577" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet", "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement", "http://cmlifesciencesspac.com/role/ConvertiblePreferredStockDetails", "http://cmlifesciencesspac.com/role/ConvertiblePromissoryNotesDetails", "http://cmlifesciencesspac.com/role/DerivativeWarrantLiabilitiesDetails", "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://cmlifesciencesspac.com/role/NatureofBusinessDetails", "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails", "http://cmlifesciencesspac.com/role/ScheduleofbasicanddilutednetincomelosspercommonshareTable", "http://cmlifesciencesspac.com/role/ScheduleofoutstandingConvertiblePreferredStockTable", "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3", "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3_Parentheticals", "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r50", "r66", "r67", "r68", "r113", "r114", "r115", "r117", "r122", "r124", "r139", "r187", "r293", "r296", "r347", "r348", "r349", "r373", "r374", "r408", "r422", "r423", "r424", "r425", "r426", "r428", "r548", "r549", "r550", "r601" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/DerivativeWarrantLiabilitiesDetails", "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails", "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet", "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow", "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement", "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3", "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3_Parentheticals" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r113", "r114", "r115", "r139", "r495" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet", "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow", "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement", "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3", "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3_Parentheticals" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r23", "r24", "r296" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Additional purchase of shares" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r49", "r250", "r293", "r294", "r296" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Issuance of Series A convertible preferred stock, net of issuance costs (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Issuance of Class B common stock to Sponsor (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r23", "r24", "r293", "r296" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock (in Shares)", "verboseLabel": "Purchase of additional shares (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails", "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Shares, Other", "terseLabel": "Issuance of Series B convertible preferred stock, net of issuance costs (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock Issued During Period, Shares, Purchase of Assets", "terseLabel": "Committed purchase warrants" } } }, "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/PrivatePlacementDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r293", "r296" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Vesting of restricted common stock (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares (or other type of equity) forfeited during the period.", "label": "Shares Issued, Shares, Share-based Payment Arrangement, Forfeited", "terseLabel": "Founder Shares no longer subject to forfeiture" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r23", "r24", "r293", "r296", "r326" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Options, Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofstockoptionactivityforemployeeandnonemployeeawardsTable" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r50", "r293", "r296" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Issuance of Series A convertible preferred stock, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Issuance of Class B common stock to Sponsor" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r23", "r24", "r293", "r296" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Value, Other", "terseLabel": "Purchase price of founder shares (in Dollars)" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock Issued During Period, Value, Purchase of Assets", "terseLabel": "Sponsor transferred founder shares" } } }, "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r23", "r24", "r293", "r296" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Vesting of restricted common stock" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r23", "r24", "r296", "r319", "r332" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Stock-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Number of stock bought back by the entity at the exercise price or redemption price.", "label": "Stock Redeemed or Called During Period, Shares", "terseLabel": "Class A common stock subject to possible redemption (in Shares)" } } }, "localname": "StockRedeemedOrCalledDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRedeemedOrCalledDuringPeriodValue": { "auth_ref": [ "r293" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.", "label": "Stock Redeemed or Called During Period, Value", "terseLabel": "Class A common stock subject to possible redemption" } } }, "localname": "StockRedeemedOrCalledDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r24", "r28", "r29", "r107", "r173", "r186", "r421", "r459" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet", "http://cmlifesciencesspac.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "netLabel": "Stockholders\u2019 deficit:", "terseLabel": "Stockholders\u2019 Equity:", "verboseLabel": "Stockholder\u2019s Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r105", "r277", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r289", "r290", "r292", "r296", "r298" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplit": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.", "label": "Stockholders' Equity Note, Stock Split", "terseLabel": "Stock split, description" } } }, "localname": "StockholdersEquityNoteStockSplit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Stockholders' Equity, Reverse Stock Split", "terseLabel": "Reverse stock split, description" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r429", "r461" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails", "http://cmlifesciencesspac.com/role/StockholdersEquityDetails", "http://cmlifesciencesspac.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r429", "r461" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails", "http://cmlifesciencesspac.com/role/StockholdersEquityDetails", "http://cmlifesciencesspac.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r429", "r461" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails", "http://cmlifesciencesspac.com/role/StockholdersEquityDetails", "http://cmlifesciencesspac.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r460", "r462" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails", "http://cmlifesciencesspac.com/role/CommitmentsandContingenciesDetails", "http://cmlifesciencesspac.com/role/DescriptionofOrganizationandBusinessOperationsDetails", "http://cmlifesciencesspac.com/role/FairValueMeasurementsDetails", "http://cmlifesciencesspac.com/role/InitialPublicOfferingDetails", "http://cmlifesciencesspac.com/role/PrivatePlacementDetails", "http://cmlifesciencesspac.com/role/ProposedPublicOfferingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of noncash activities:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.", "label": "Temporary Equity, Accretion to Redemption Value, Adjustment", "terseLabel": "Net income allocable to Class A common stock" } } }, "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofbasicanddilutednetincomelosspercommonshareTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate amount of redemption requirements for each class or type of redeemable stock classified as temporary equity for each of the five years following the latest balance sheet date. The redemption requirement does not constitute an unconditional obligation that will be settled in a variable number of shares constituting a monetary value predominantly indexed to (a) a fixed monetary amount known at inception, (b) an amount inversely correlated with the residual value of the entity, or (c) an amount determined by reference to something other than the fair value of issuer's stock. Does not include mandatorily redeemable stock. The exception is if redemption is required upon liquidation or termination of the reporting entity.", "label": "Temporary Equity, Aggregate Amount of Redemption Requirement", "terseLabel": "Common stock, shares subject to possible redemption" } } }, "localname": "TemporaryEquityAggregateAmountOfRedemptionRequirement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r219", "r224", "r225", "r226", "r230", "r231" ], "calculation": { "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "terseLabel": "Class A common stock, $0.0001 par value; 46,721,452 shares subject to possible redemption at $10.00 per share" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityNetIncome": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of net income or loss attributable to temporary equity interest.", "label": "Temporary Equity, Net Income", "terseLabel": "Net loss" } } }, "localname": "TemporaryEquityNetIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/NatureofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r10", "r268" ], "lang": { "en-us": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Temporary Equity, Par or Stated Value Per Share", "terseLabel": "Common stock, shares subject to possible redemption par value (in Dollars per share)" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquityRedemptionPricePerShare": { "auth_ref": [ "r10", "r268" ], "lang": { "en-us": { "role": { "documentation": "Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Redemption Price Per Share", "terseLabel": "Common stock, shares subject to possible redemption at per share (in Dollars per share)" } } }, "localname": "TemporaryEquityRedemptionPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Issued", "terseLabel": "Aggregate of founder shares (in Shares)" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Outstanding", "terseLabel": "Aggregate of founder shares outstanding (in Shares)" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r180", "r181", "r182", "r183", "r184", "r258", "r291", "r407", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r577", "r578", "r579", "r580", "r581", "r582", "r583" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofassetsthataremeasuredatfairvalueonarecurringbasisTable0" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r361" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "terseLabel": "Total unrecognized compensation expense (in Dollars)" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/StockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationImputedInterest": { "auth_ref": [ "r213" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "If disclosed, the amount of imputed interest necessary to reduce an unconditional purchase obligation to present value on an unrecorded unconditional purchase obligation.", "label": "Unrecorded Unconditional Purchase Obligation, Imputed Interest", "negatedLabel": "Less: Imputed interest" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationImputedInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleoftotalleasepaymentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r144", "r145", "r147", "r148", "r149", "r150", "r151" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r440", "r445" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease costs", "verboseLabel": "Variable lease costs(1)" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ScheduleofleasecostsintheCompanyscondensedconsolidatedstatementsofoperationsandcomprehensivelossTable", "http://cmlifesciencesspac.com/role/ScheduleofoperationsandcomprehensivelossTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Private Placement Warrants [Member]", "verboseLabel": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/DerivativeWarrantLiabilitiesDetails", "http://cmlifesciencesspac.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrant term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/StockholdersEquityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Weighted average shares outstanding, basic and diluted (in Shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r125", "r134" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares (in Shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cmlifesciencesspac.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(b))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r112": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r138": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r152": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27405-111563" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=29634951&loc=d3e1756-110224" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2459-110228" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r209": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25376-109308" }, "r214": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r216": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=28183603&loc=d3e692-112598" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r266": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(12)(c)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(16)(c)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(3)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "14", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "15", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21332-112643" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21346-112643" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r298": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r353": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.15)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=d3e5283-111683" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r398": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123420820&loc=SL77919306-209978" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r455": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r462": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.13(h))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.14)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(23)(a)(4)(i))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8,17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.7)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=35755530&loc=d3e11264-158415" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(30)(a)(3)(ii))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r576": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r577": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r578": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r579": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r580": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r581": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r582": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r583": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r584": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r585": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r586": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r587": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column B", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r588": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column C", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r589": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column D", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r590": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column E", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r591": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column F", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r592": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column G", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r593": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column H", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r594": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column I", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r595": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "a", "Publisher": "SEC", "Section": "12", "Subsection": "04" }, "r596": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(i)", "Subsection": "01" }, "r597": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "01" }, "r598": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "02" }, "r599": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "i", "Publisher": "SEC", "Section": "3", "Subsection": "10" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r600": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1)(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868656-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(2))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(2))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4,6)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080555-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" } }, "version": "2.1" }